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ABSTRACT 
It is well recognized that the global increase in obesity and metabolic diseases over 
the last several decades cannot be solely attributed to aging and modern lifestyle trends 
(i.e.,  excess caloric intake and lack of physical activity). Metabolism disrupting chemicals 
(MDCs) are environmental and consumer product chemicals that act at the molecular level 
in multiple organs to affect systemic metabolic homeostasis and are hypothesized to 
increase the risk of obesity and metabolic diseases. The nuclear receptor peroxisome 
proliferator activated receptor γ (PPARγ) regulates insulin sensitivity, adipogenesis, and 
mature adipocyte maintenance, function and survival, which make it beneficial as a 
therapeutic target. However, PPARγ is also a target for structurally diverse MDCs that may 
not induce its health-promoting biological effects. One such PPARγ agonist is triphenyl 
phosphate (TPHP), an organophosphate ester commonly used in consumer products. 
Accumulating evidence from animal and in vitro studies demonstrates that MDCs act on 
multiple organs (e.g., liver, adipose, pancreas) to disrupt glucose and lipid homeostasis. 
Epidemiological studies have characterized human exposure to complex mixtures of 
MDCs and associated that exposure to obesity and metabolic diseases. However, not all 
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suspected MDCs have been investigated in human epidemiological studies. Furthermore, 
these studies are complicated given the role of complex chemical mixtures. The objectives 
of this dissertation were: 1) to investigate the role of TPHP, a suspected MDC in animal 
studies, as a metabolic disruptor in humans, 2) to develop an improved biomarker of 
exposure to mixtures of environmental PPARγ ligands, the Serum PPARγ Activity Assay 
(SPAA), and 3) to investigate environmental exposures in a human cohort using the SPAA. 
In the first aim, we used publicly available data from the 2013-2014 National Health and 
Nutrition Examination Survey to investigate the association between urinary diphenyl 
phosphate (DPHP), a metabolite of TPHP and biomarker of exposure, and measures of 
body adiposity as well as markers of type 2 diabetes risk. In adjusted multivariate linear 
regression models, urinary DPHP was positively associated with increased waist 
circumference, body mass index, and sagittal abdominal diameter in adults aged 20-50 
years, but not in older adults aged 51-79 years. In all adults, urinary DPHP was not 
associated with any marker of type 2 diabetes risk (fasting plasma glucose, hemoglobin 
A1c, homeostatic model assessment of insulin resistance, 2-hour oral glucose). In the 
second aim, we developed and optimized the SPAA as a tool to measure cumulative PPARγ 
ligand activity in human serum samples and then used the assay to assess exposure to 
PPARγ ligands in a human cohort. SPAA generates robust PPRE transcriptional activity 
using Cos-7 cells transfected with a human PPARγ1 expression vector along with a PPRE 
(DR1)-driven luciferase vector. With small volumes of serum, the SPAA reliably detected 
high PPRE transcriptional activity levels induced by rosiglitazone, a potent and efficacious 
therapeutic PPARγ agonist, in serum from experimentally exposed mice. The SPAA also 
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detected significant differences in the PPRE transcriptional activity induced by U.S. based 
human commercial serum samples. The abrogation of the activity by a PPARγ antagonist, 
T0070907, confirmed the receptor-specificity of the human serum-induced activity. 
Finally, we investigated PPARγ agonist exposure in serum samples from a population of 
Danish women with extensive environmental chemical biomarker data using SPAA and 
used an additivity model to estimate the contribution of a subset of the chemicals towards 
measured activity. The serum samples from the Danish cohort induced PPRE 
transcriptional activity in the SPAA, but with an overall lower efficacy than a U.S. based 
serum samples. Modeling of the PPRE transcriptional activity induced by the 
perfluoroalkyl substances and a polybrominated diphenyl ether at concentrations measured 
in the Danish serum with effect summation demonstrated that these chemicals are unlikely 
to be the source of the serum activity. Together, these findings demonstrate that TPHP 
exposure is associated with metabolic disruption, specifically adiposity, in people, which 
supports toxicological research, and lay the foundation for future work using the SPAA as 
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Chapter 1: Introduction 
Obesity and Metabolic Syndrome Epidemic 
The rise in obesity prevalence over the past several decades is not entirely explained 
by genetics, physical inactivity, and excess caloric intake. Obesity is defined as excessive 
or abnormal fat accumulation that may impair a person’s health and is commonly measured 
using body mass index (BMI). The World Health Organization (WHO) estimates that 39% 
of adults worldwide are obese (i.e., have a BMI greater than or equal to 30 kg/m2 ) [1]. In 
the U.S., 60% of obese individuals have metabolic syndrome compared to 5% of normal-
weight individuals [2]. Metabolic syndrome is a cluster of comorbidities that includes high 
blood pressure, high blood sugar, excess central adiposity, and dyslipidemia [3]. Metabolic 
syndrome, in turn, substantially increases the risk of type 2 diabetes as well as other 
metabolic diseases such as atherosclerosis, and non-alcoholic fatty liver disease [1]. Thus, 
it is not surprising that global rates of type 2 diabetes also are rising; the International 
Diabetes Federation (IDF) estimates the number of adults with diabetes (both type 1 and 
2) will increase by 48% by 2045 globally [4]. Type 2 diabetes, defined by the body’s 
ineffective use of insulin as well as a failure of the pancreas to generate enough insulin to 
control blood glucose, accounts for 90% of all diabetes cases, and unlike type 1 diabetes, 
or non-insulin dependent diabetes, type 2 diabetes is largely preventable and manageable 





PPARγ and Metabolic Homeostasis  
Whole body metabolic homeostasis is regulated by multiple organs that are 
regulated by the endocrine system [5]. Adipose tissue, once thought to be a passive energy 
depot, is widely recognized as an endocrine organ responsible for the synthesis and 
breakdown of triglycerides and release of fatty acids and adipokines into circulation [6]. 
These nutrients, metabolites, and hormones are dispersed throughout the body via the 
circulatory system to other organs such as the pancreas, liver, bone and kidney to maintain 
metabolic homeostasis. Disruptions in functions of these organs can be communicated 
throughout the body via changing levels in circulating nutrients and metabolites thus 
perturbing metabolic processes and setting the stage for metabolic disruption [7].  
Increased white adipose tissue expansion is the defining characteristic of obesity; 
however, obesity itself is not necessarily an indicator of metabolic disease. Some obese 
individuals are free from any obesity-related complications (i.e., no dyslipidemia, insulin 
resistance, or hypertensions); this healthier phenotype is referred to as metabolically 
healthy obesity (MHO). Although the of prevalence MHO is still debated, MHO 
individuals have more subcutaneous fat compared to visceral fat and ectopic fat around the 
organs which is related to metabolic abnormalities [8]. Adipose tissue expansion 
contributes to disease when adipose tissue expansion diminishes its functionality. Both the 
volume and quality of adipose tissue, comprised of adipocytes, are associated with risk of 
disease [9, 10]. Adipose tissue growth that outpaces the generation of new blood vessels 
can cause hypoxia and ultimately fibrosis and inflammation [11]. The inability of adipose 




pancreas, liver and muscle (i.e., lipotoxicity) [12]. Furthermore, adipose tissue can secrete 
proinflammatory cytokines (TNF-α and IL-6) that block the action of insulin in other parts 
of the body such as skeletal muscle and liver [13-15]. As a result, insulin sensitivity is 
decreased.  
Regulation of adipose and metabolic homeostasis occurs in part through ligand-
activated transcription factors, which control gene expression. The nuclear receptor 
peroxisome proliferator activated receptor gamma (PPARγ) regulates differentiation of 
white, brown, and brite (brown-in-white) adipocytes (i.e. adipogenesis), mature adipocyte 
maintenance, function and survival, insulin sensitivity, immune response, and the balance 
of adipogenesis and osteogenesis [16-20]. PPARγ binds to the PPAR response element 
(PPRE, 5’-CAAAACAGGTCANAGGTCA-3’) heterodimerized with the retinoid x 
receptors (RXR) to regulate gene transcription [21]. Mammals express two different 
isoforms of PPARγ, PPARγ1 and PPARγ2, due to differential splicing and alternative 
promoter usage of the PPARγ gene. PPARγ1 is broadly expressed in tissues such as liver, 
muscle, heart, spleen, adipose, and kidney [22, 23]. PPARγ2 has an additional 30 extra 
amino acids at the proximal end of the N-terminus and is highly expressed only in adipose 
tissues [24, 25]. 
Endogenous ligands for PPARγ include small lipophilic compounds such as fatty 
acids and prostaglandins [26]. The activity of these compounds is necessary for the healthy 
and normal remodeling of adipose tissue. Defects in PPARγ can negatively affect 
metabolic health. Lack of PPARγ results in lipodystrophy, hepatic steatosis, lack of insulin 





Because of its role as regulator of adipose tissue function, which is critical to overall 
insulin sensitivity, PPARγ is also a therapeutic target. Rosiglitazone (trade name Avandia), 
part of the thiazolidinedione class of drug, is a highly potent PPARγ agonist that is used in 
the treatment of type 2 diabetes that acts by upregulating PPARγ’s insulin sensitizing 
functions [31, 32]. Additionally, rosiglitazone also activates PPARγ’s pro-adipogenic and 
anti-osteogenic functions. Patients using rosiglitazone experienced increased weight gain 
and risk of bone fracture [33, 34].  
Upon binding by a ligand, the PPARγ-RXRα heterodimer undergoes a 
conformational change to facilitate gene transcription. Ligands facilitate or prevent 
differential post-translational modifications of PPARγ that change the expression of genes 
involved in insulin signaling, lipid transport and metabolism, and adipokine production 
[32, 35]. Growing evidence shows that ligand-dependent changes in post-translational 
modifications can determine the release of co-repressors and the selective recruitment of 
specific co-regulators [36-39]. For example, rosiglitazone inhibits phosphorylation of the 
amino acid serine 273 on PPARγ and this modification leads to improved insulin sensitivity 
[32, 40].   
 
PPARγ Beyond Adipose   
 The biological effects of PPARγ are not limited to adipose tissue. PPARγ also 
regulates bone homeostasis and immune response and plays an important role in the brain 




suppresses osteoblast formation and induces adipogenesis resulting in decreased bone 
formation [44]. Activation of PPARγ exerts anti-inflammatory effects. For instance, in the 
central nervous system, activation of PPARγ has been proposed as protective of 
neurodegeneration due to the anti-inflammatory effects in microglia and astrocytes [45, 
46]. In lung macrophages, PPARγ activity helps to ensure proper functioning during 
respiratory viral infections [47]. Furthermore, evidence suggests that neuronal expression 
of PPARγ plays a key role in the regulation of energy homeostasis and weight gain [48, 
49].  
 
PPARγ as a target for environmental and consumer product chemicals 
 Over the past decades, thousands of chemicals have been registered for use in 
industry, agriculture, and consumer products. Endocrine disrupting chemicals (EDCs) are 
exogenous compounds that interfere with secretion, elimination, metabolism, or action of 
hormones that regulate body systems and homeostatic mechanisms [50]. The term 
“obesogen” was coined in 2006 to describe a subset of environmental EDCs that contribute 
to the risk of obesity by inducing inappropriate lipid accumulation and adipogenesis [51, 
52]. This term evolved into “metabolism disrupting chemicals” (MDCs). The revised 
terminology acknowledges environmental chemicals that not only increase adipose mass, 
but also act through other molecular pathways to set the stage for metabolic syndrome and 
disease [5]. 
 A focus of MDC research has been on identifying chemicals that activate PPARγ. 




diverse chemicals belonging to several different classes. Examples of select chemicals are 
described below.   
Phthalates are produced in high volume for use as plasticizers in food packaging, 
cosmetics, personal care products, and medical devices [53]. Research regarding the 
obesogenic effects of phthalates has focused on di-(2-ethylhexyl) phthalate (DEHP) and its 
monoester metabolite mono-(2-ethylhexyl) phthalate (MEHP); however, multiple 
phthalates have been found to activate PPARγ [54-58]. MEHP induces adipogenesis by 
activating PPARγ in 3T3-L1 cells and induces adipogenesis while suppressing 
osteogenesis by activating PPARγ in primary mouse bone marrow culture models [54, 59-
62]. Furthermore, MEHP induces expression of PPARγ target genes adiponectin, Lpl, and 
Fabp4 [55, 61]. In male mice, perinatal exposure to MEHP increased body weight, fat 
mass, and glucose levels [63]. In mice expressing human PPARα, an isoform responsible 
for fatty acid oxidation and lipid metabolism, oral exposure to DEHP caused increased fat 
accumulation and obesity suggesting that MEHP might be obesogenic through multiple 
pathways [64]. 
Bisphenols are a class of synthetic chemicals used in plastics manufacturing [65]. 
Bisphenol A (BPA), the most commonly studied compound, promotes adipogenesis in 
mouse preadipocytes and activates PPARγ, albeit at a lower efficacy than its halogenated 
analog tetrabromobisphenol A [66, 67]. Prenatal exposure to BPA, at human relevant 
concentrations, increased postnatal body weight gain, abdominal fat and impaired glucose 
tolerance and insulin sensitivity in mice [68]. Additionally, another study reported changes 




maternal exposure to BPA [69].  
Triphenyl phosphate (TPHP) is an organophosphate ester (OPEs) used as a flame 
retardant, often as part of the commercial mixture Firemaster 550, in polyurethane foam 
and as a plasticizer in lacquers, nail polish, hydraulic fluids, and varnishes [70]. Since the 
phase out of polybrominated diphenyl ethers (PBDEs) as an industrial chemical additive, 
OPEs have increased in use [71, 72]. TPHP activates PPARγ in reporter assays and induces 
adipogenesis in mouse bone marrow stromal cells and human primary adipocytes [73-75]. 
Animal studies have focused primarily of the effects of early life TPHP exposure on 
metabolic health in rodents. Prenatal exposure to TPHP caused weight gain, increased 
plasma fatty acids, and accelerated onset of disease in type 2 diabetes-prone rats [76, 77]. 
Similarly, in utero and lactational exposure to TPHP increased body weight, fat mass, 
hepatic steatosis, impaired glucose homeostasis, and insulin resistance in male mice; 
similar results were seen in male mice following neonatal exposure [78, 79].  
Per- and poly-fluoroalkyl substances (PFAS) are a family of highly persistent 
synthetic chemicals that are used in household products, textiles, and food packaging to 
provide water, oil, and stain repellency as well as in fire-fighting foam [80, 81]. Both 
perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) were phased out 
of use in the U.S. in 2015 and 2002 respectively. While PFOA and PFOS body burdens are 
decreasing in most countries (with the exception of China), generation of replacement 
PFASs means that exposure to this class of chemicals continues [82-84]. Aside from PFOS 
and PFOA, evidence regarding toxicity and potential risk to human health is limited for the 




(PFDeA) induce significant PPARγ activity in reporter assays [85]. PFOA and PFOS, the 
most widely studied PFASs, induce adipocyte differentiation in mouse preadipocytes and 
expression of PPARγ specific target genes [86-88]. Furthermore, long chain PFASs induce 
the expression of PPARγ target genes in human mesenchymal stem cells with a dose-
dependent relationship between PFOS and PFOA and Ap2 [89]. In mice, exposure to low 
doses of PFOA during pregnancy led to increased body and organ weight and leptin and 
insulin levels during adulthood; there were no significant effects at high doses [90]. In two 
separate studies, perinatal and gestational and lactational exposure to PFOS led to increased 
insulin resistance, glucose intolerance, and elevated insulin levels in rodents [91, 92]. 
Conversely, another study found no changes to body weight gain or blood glucose 
measures in mice after in utero exposure to PFOA or PFOS [93].  
 
Environmental PPARγ Ligands and Human Health    
Over the past decade, studies have begun to connect human exposure to 
environmental MDCs and obesity and metabolic health related outcomes. While in vitro 
and animal studies support the role of environmental chemicals as metabolic disruptors, 
results from epidemiological findings are mixed and often limited for some classes of 
chemicals. Cross-sectional analyses of data from the National Health and Nutrition 
Examination Survey (NHANES) found increases in BMI and waist circumference (WC) 
across quartiles of mono-benzyl phthalate (MBzP) in adult men and across quartiles of 
mono-ethyl phthalate (MEP) in adolescent females. Conversely, MEHP was inversely 




associations between several urinary phthalate monoesters and WC and homeostatic 
modeling assessment (HOMA), a measure of insulin resistance, in males in adjusted 
models [95]. In longitudinal analyses, mono-(2-ethyl-5-oxohexyl) phthalate, MEP, mono-
hydroxybutyl phthalate, and mono-hydroxyisobutyl phthalate, were associated with 3-year, 
but not 6-year, weight gain in postmenopausal women [96]. Positive associations between 
phthalates and type 2 diabetes are largely limited to cross-sectional studies, in which 
metabolites of DEHP and MzBP were associated with the outcome [97, 98]. 
Human exposure to BPA is widespread due to its use in plastic food and beverage 
packaging and tin can lining [65]. In data from NHANES, increases across quartiles of 
urinary BPA were associated with higher BMI in children in adjusted models [99]. 
Similarly, in a national representative sample of the general Canadian population, urinary 
BPA was positively associated with BMI, but not WC, in adults [100]. Urinary BPA 
concentrations were positively associated with higher odds of type 2 diabetes and higher 
hemoglobin A1c in adults in NHANES [101]. Results from a prospective investigation of 
the Nurse’s Health Study II demonstrate that urinary BPA is positively associated with type 
2 diabetes, although findings were only statistically significant after adjusting for BMI 
[102]. 
TPHP is used in consumer products, however, it is not chemically bound and easily 
migrates into the surrounding environment. In humans, TPHP is rapidly broken down into 
a diester, diphenyl phosphate (DPHP) [103], which is commonly used as a biomarker of 
exposure to TPHP in human epidemiological and exposure assessment studies [104-106]. 




humans. The study was conducted using OPE metabolite data from NHANES. While 
urinary DPHP was not significantly associated with any outcomes related to adiposity in 
children or adults, evidence suggest differences by sex. In males, urinary DPHP was 
positively associated with increased BMI and increased prevalence odds of having higher 
WC vs. normal WC; in females, there was an inverse association [107]. The study did not 
investigate any outcomes related to diabetes. 
PFASs are used in industrial and consumer products, and at least PFOA and PFOS 
are detected in drinking water at levels that may exceed the U.S. Environmental Protection 
Agency health advisory limit [108]. Cross-sectional evidence linking PFAS exposure to 
increased weight gain and metabolic health parameters were mixed [109-111]. For 
example, one study in NHANES found positive associations between serum PFOA and 
diabetes prevalence in men [110]. Another study in NHANES found a positive association 
between PFNA and increased WC, serum triglycerides, and fasting glucose; yet, no 
significant associations were found with other PFASs, including PFDeA, PFOA, PFOS, 
PFHxS [111]. Several prospective studies have investigated prenatal and early life PFAS 
exposure and metabolic parameters and weight gain later in life. In a population exposed 
to drinking water contaminated with PFOA from a nearby chemical plant, early life 
exposure was not associated with increased BMI or risk of being overweight in adults 
[112]. Another study reported positive associations between serum PFOA concentrations 
in pregnant women and risk of being obese and overweight, however, these findings were 
limited to adult women not men [113]. In addition, two prospective studies reported higher 




prospective studies found positive associations between serum PFAS levels and increased 
weight gain and adverse lipid profiles in adults. However, these results were stronger in 
groups randomized to receive no lifestyle interventions which suggests that diet and 
behavioral factors can modify the risk associated with MDCs [116, 117]. 
 
Research Objectives 
Environmental and consumer product chemicals that target PPARγ and disrupt its 
metabolic functions include a lengthy list of chemicals that are ubiquitous in the 
environment and contribute to a complex chemical mixtures problem. Research has 
focused on the role of environmental chemicals that activate PPARγ as additional risk 
factors contributing to the development of obesity, diabetes, and other metabolic diseases. 
In the past decade, both animal and human studies have connected environmental PPARγ 
ligand exposure to weight gain, insulin resistance, and high blood sugar. Animal studies to 
date suggest TPHP’s role as an MDC, yet there is limited evidence in human 
epidemiological studies regarding the association between environmental TPHP and 
adverse metabolic effects. The substitution of PBDEs for OPEs, such as TPHP, means 
TPHP exposure is nearly ubiquitous, particularly in houses, offices, and public spaces. As 
a result, more studies are needed to understand the potential metabolic health effects 
associated with environmental TPHP exposure. Furthermore, in addition to TPHP, humans 
are exposed to countless other environmental and consumer product chemicals. Some of 
these chemicals can disrupt PPARγ’s role in adipose and metabolic homeostasis and others 




Traditional methods that focus on studying a single chemical at a time fail to capture real-
world exposure scenarios. A cumulative assessment of ligand induced PPARγ activity is 
warranted in light of the facts that humans are exposed to complex mixtures of these 
chemicals and that PPARγ regulates important biological functions.  
In Chapter 2, we investigated the role of TPHP as a metabolic disruptor in adults in 
the U.S. general population using data from NHANES. We examined exposure to TPHP 
using urinary DPHP in relation to multiple measures of metabolic health, including 
measures of type 2 diabetes risk (fasting plasma glucose, hemoglobin A1c, homeostatic 
model assessment of insulin resistance, 2-hour oral glucose) and body adiposity (body mass 
index, waist circumference, sagittal abdominal diameter). Using demographic, 
socioeconomic, and questionnaire data from NHANES, we included information on 
potential confounders in our models and evaluated the potential effect measure 
modification by sex, menopausal status (i.e., estrogen), and age. 
Taking into account the growing literature on exogenous chemical disruption of 
PPARγ’s functions, in Chapter 3, we developed and tested the applicability of the Serum 
PPARγ Activity Assay (SPAA) as a simple, cost-effective biomarker of exposure to 
mixtures of environmental PPARγ ligands. We optimized the assay to measure PPARγ-
specific activity using serum from mice exposed to known quantities of PPARγ ligands 
and commercially available human serum samples. Next, in Chapter 4, we used the assay 
to assess exposure to environmental and consumer product chemicals in serum samples 
from the Snart Foraeldre/Milieu study, a previously established prospective cohort study 
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Background: Exposure to triphenyl phosphate (TPHP) is ubiquitous and animal studies 
suggest that TPHP may act as a metabolism disrupting chemical. However, there is a lack 
of evidence from human studies. 
 
Objective: We evaluated cross-sectional associations of urinary diphenyl phosphate 
(DPHP), a primary metabolite of TPHP, with markers of diabetes risk (fasting plasma 
glucose, hemoglobin A1c, homeostatic model assessment of insulin resistance, 2-hour oral 
glucose), and measures of body adiposity (waist circumference (WC), body mass index 
(BMI), and sagittal abdominal diameter (SAD)). 
 
Methods: We used data from 1203 adults participating in the National Health and Nutrition 
Examination Survey 2013-2014. We used multivariate regression modeling to assess 
associations between quartiles of urinary DPHP excretion rate and measures of diabetes 
risk and body adiposity. We also tested for effect measure modification by sex, menopausal 
status, and age. 
 
Results: In adjusted models, urinary DPHP was positively associated with all body 
adiposity measures. In stratified analyses with WC, BMI, SAD, associations were stronger 
in younger adults compared to older adults. For example, young adults in the fourth quartile 
of DPHP had higher WC (Q4: β=9.05 cm, 95% CI: 7.23, 10.88) compared to young adults 




95% CI: -2.40, 7.04). Urinary DPHP was not associated with any diabetes risk biomarker. 
 
Conclusions: Urinary DPHP is positively associated with body adiposity measures in 
adults in the U.S. general population, particularly young adults. These results suggest 






Organophosphate esters (OPEs) are a group of chemicals used in commercial and 
consumer products to increase plasticity and reduce flammability [72]. Since the phase out 
of polybrominated diphenyl ethers (PBDEs), a class of brominated chemicals used as flame 
retardants, the use of OPEs in products such as hydraulic fluids, electronic equipment, 
rubber, textiles, and cotton has increased [71] [72]. Triphenyl phosphate (TPHP) is used as 
a flame retardant, often as part of the commercial mixture Firemaster 550, in polyurethane 
foam and as a plasticizer in lacquers, nail polish, hydraulic fluids, and varnishes [70].   
As a chemical additive, TPHP is not chemically bound to a product and can enter 
the surrounding environment. The migration of TPHP from materials results in widespread 
environmental contamination; TPHP has been detected in indoor dust from furniture, 
schools, households, offices, and public environments, outdoor and indoor air, sewage 
water effluent, surface water, and in fish [118-126]. The general population is exposed to 
TPHP through ingestion of household dust, inhalation of dust and vapors, and dermal 
absorption from contact with dust, source products, and vapors [74].    
Based on toxicokinetic research, TPHP is rapidly broken down into a diester, 
diphenyl phosphate (DPHP), and sulfate and glucuronide conjugates [103]. Although there 
are other sources of DPHP in the environment, [127] urinary DPHP has been commonly 
used to document TPHP exposure, and a few studies have reported differences in exposure 
by sex [104-106].    
TPHP is considered an environmental metabolism disrupting chemical (MDC) [5]. 




hormones to receptors that regulate multiple aspects of physiological homeostasis. The 
metabolism disrupting chemical hypothesis proposes that environmental MDCs can 
“promote metabolic changes that can result in obesity, type 2 diabetes, or fatty liver in 
animals including humans; these metabolic alterations may play an important role in the 
global epidemics of obesity, type 2 diabetes, and metabolic syndrome” [5]. 
Animal studies have linked TPHP exposure to weight gain, insulin resistance, and 
early onset type 2 diabetes, and some results suggest the effects of TPHP may differ by sex 
[76-79]. Furthermore, many studies report that TPHP likely exerts its biological effects 
through activation of the nuclear receptor peroxisome proliferator activated receptor-
gamma (PPARγ) [73-75, 128]. PPARγ regulates adipocyte (fat cells that store lipids) 
formation, function, and insulin sensitivity [129]. In the past decade, several environmental 
MDCs that activate PPARγ, such as phthalates and phenols, have been linked to outcomes 
related to metabolic dysfunction in both animal and human studies [64, 69, 94, 130-134]. 
Despite the growing experimental evidence of TPHP’s role as an MDC, there are 
few human studies investigating the association between TPHP and adverse health effects 
related to endocrine and metabolic disruption. In a cohort of men and women from Boston, 
TPHP exposure was related to subclinical changes in thyroid function [135]. Another study 
of men recruited from infertility centers investigated the association between TPHP 
exposure and semen quality and hormone levels [136-138]. One study investigated the 
association between urinary DPHP and adiposity using data from NHANES. Researchers 
found positive albeit not significant associations between urinary DPHP and BMI and WC 




associations among TPHP exposure and outcomes related to diabetes risk.   
The current study examined the relationship between urinary DPHP and biomarkers 
of type 2 diabetes risk (i.e., long- and short-term measures of blood glucose and insulin 
sensitivity) and measures of body adiposity using data on adults who participated in the 
National Health and Nutrition Examination Survey (NHANES) during 2013–2014. We 
used multiple biomarkers of diabetes risk and markers of body adiposity. We used urinary 
DPHP modeled as a urinary excretion rate as our measure of exposure, and we addressed 
potential effect measure modification by sex, estrogen, and age. Sex-specific differences 
in insulin resistance, glucose homeostasis, and adipose tissue metabolism are well-
documented and have been linked to the effects of estrogen [139-141]. 
 
Materials and Methods 
Study Participants 
NHANES is conducted by the National Center for Health Statistics (NCHS) and is 
a nationally representative random sample of the non-institutionalized U.S. population 
where participants are selected using a complex multistage sampling strategy. A suite of 
OPE metabolites were measured in the 2013–2014 cycle of NHANES. Additionally, 
NCHS collected data on demographic, dietary, and lifestyle factors using in-home 
questionnaires and anthropometric information through physical examinations in mobile 
examination units. The NHANES study was approved by the NCHS Research Ethics 
Review Board and written informed consent was collected from all NHANES participants. 




and 79 years with measures of urinary DPHP, urine flow rate, urinary creatinine, data on 
menopause, and one of the metabolic outcomes. We excluded participants diagnosed with 
diabetes or currently taking medications to treat diabetes (N=140) and women who were 
pregnant or breastfeeding (N=22). Additionally, we excluded participants with chronic 
kidney disease (CKD) defined as a self-report of dialysis in the past 12 months or an 
estimated glomerular filtration rate less than 60 mL/min/1.73 m2 using the Chronic Kidney 
Disease Epidemiology Collaboration equation [142] because of CKD’s effect on urine 
output and urinary creatinine (N=73).   
 
Exposure Assessment 
DPHP was measured in stored spot urine samples from a random sample of one 
third of the NHANES 2013–2014 population. The 2013–2014 survey cycle is the first cycle 
in which NHANES measured OPE metabolites. Details of the laboratory methods for 
measuring urinary DPHP concentrations are reported in full elsewhere [143]. Briefly, 
urinary DPHP was measured using reversed phase high-performance liquid 
chromatography separation and isotope dilution-electrospray ionization tandem mass 
spectrometry detection [144]. DPHP was detected in 99% of the samples. NHANES 
replaced DPHP measurements less than the limit of detection (LOD) with a value equal to 
the LOD divided by the square root of two [145].  
To address variation in DPHP concentrations associated with the effect of urinary 
dilution, we calculated urinary excretion rates of DPHP using individual urine flow rates 




creatinine as a covariate or using creatinine-corrected DPHP [146, 147]. NHANES 
calculated urine flow rate by dividing the volume of urine sample taken during the exam 
by the difference in time between the last urine void and the exam urine void [148]. DPHP 
urinary excretion rate (urinary DPHP) was calculated by multiplying individual urinary 
DPHP concentration by urine flow rate.  
 
Metabolic Health Measurements 
We investigated the associations between urinary DPHP and multiple biomarkers 
of diabetes risk and body adiposity. Type 2 diabetes risk markers included fasting plasma 
glucose (FPG), glycohemoglobin (HbA1c), oral glucose tolerance (2-hour glucose), and 
homeostatic modeling assessment for insulin resistance (HOMA-IR). Body adiposity 
measures included waist circumference (WC), body mass index (BMI), and sagittal 
abdominal diameter (SAD).  
FPG and 2-hour glucose levels were measured in a subsample of participants who 
met NCHS exclusion criteria such as fasting for at least nine hours and not taking insulin 
or oral medications for diabetes. FPG was measured in serum by the hexokinase enzyme 
method. Two-hour glucose levels were assessed by an oral glucose tolerance test where 
participants had their glucose measured by venipuncture before and after receiving a 75-
gram dose of glucose. HOMA-IR was calculated as fasting plasma glucose multiplied by 
fasting plasma insulin levels and divided by 22.5 [149]. HbA1c (%) was measured in whole 
blood collected from all participants during the morning examination. All biomarkers of 




laboratory methods can be found elsewhere [148]. Trained health technicians took WC, 
BMI, and SAD measurements. SAD (cm) is the distance between the front of the abdomen 
and small of the back when a participant is laying face up and is a measure of visceral fat. 
BMI (kg/m2) is the weight in kilograms divided by height in meters squared. WC (cm) is 
the measurement of a participant’s waist located right above the hip. Detailed information 
regarding examination procedures for WC, BMI, and SAD are available elsewhere [150]. 
 
Other variables 
Covariates of interest were self-reported from questionnaires. Annual household 
income was categorized as less than $20,000, $20,000 to $34,999, $35,000 to $74,999, and 
greater than $75,000 a year (reference). Education level was categorized as less than high 
school (reference), high school diploma, and at least some college. Participants could self-
identify as Non-Hispanic White (reference), Black, Multi-racial, Asian-American, 
Hispanic Mexican-American, or Hispanic Other. Smoking history was categorized as 
current, previous, or never smoker (reference). Alcohol consumption was classified into 
none (reference), less than one, one to three, four to seven, or eight or more drinks per 
week. Physical activity level was determined from questions regarding vigorous and 
moderate work and recreational activity and time spent performing each activity; the final 
variable was expressed as minutes of moderate physical activity per day. Physical activity 
was modeled continuously for regression analyses but divided into categories based on 
recommended 150-300 minutes of moderate intensity physical activity per week for 




from total dietary fat in analyses to address the effect of fat intake as it is related to overall 
diet quality. The mean dietary fat (gram) collected from the two records of dietary 
information was converted to energy (9 gram/kcal) and divided by the mean total energy 
(kcal) collected from dietary records to get the final variable [152]. The final variable was 
modeled continuously in regression analyses and divided into dietary relevant categories 
for descriptive statistics [153]. Hormone replacement use amongst post-menopausal 
women was assessed based on questions on use of estrogen only or estrogen/progestin 
combination patches and pills. Menopausal status was based on questions regarding last 
menstrual cycle in the past 12 months or previous hysterectomy or removal of ovaries. A 
variable of the six month time-period within which the examination was performed 
(November 1st – April 30th or May 1st – October 31st) was included in analyses to address 
research that suggests exposure to TPHP and weight may vary seasonally [154, 155]. 
 
Statistical Analyses  
We used separate multiple linear regression models to examine the relationships 
between urinary DPHP and each marker of diabetes risk and measure of body adiposity 
while controlling for potential confounding variables. Because of the skewed distributions, 
we log transformed FPG, 2-hour glucose, HOMA-IR, and HbA1c measures in our models. 
We controlled for variables in the model that were potentially associated with TPHP 
exposure and diabetes biomarkers and body adiposity measures. Potential confounders 
were identified a priori from directed acyclic graphs (DAGs). We included age 




covariates were included if they changed the beta estimates by 10% or greater.  
Using product interaction terms of age, sex, and menopausal status and urinary 
DPHP, we examined potential modification by age, sex, and menopausal status. For this 
purpose, we categorized age as 20–50 years and 51–79 years as a way of confirming that 
any effects by menopause were not an effect of comparing older and younger adults. P-
value ≤ 0.10 was considered significant effect modification. Urinary DPHP was expressed 
in quartiles determined for each outcome to assess non-linear relationships between the 
exposure and the outcomes. Tests for trend were performed by assigning the median of 
each quartile as a continuous variable in the multivariate models. All analyses were 
conducted in SAS version 9.3 and were performed using sample weights and strata and 
cluster variables to account for NHANES’ complex, multistage sampling design.  
The variables percent total energy from dietary fat and income were missing for 
9% and 15% respectively of the study population. We imputed diet and physical activity 
using the fully conditional specification (FCS) method, which imputes missing data for 
both continuous and categorical variables and allows variable-by-variable specification of 
the imputation method [156, 157]. Percent total energy from dietary fat was imputed using 
the regression method and income was imputed using the discriminant function, the default 
method for classification variables. All outcome variables and covariates of interests were 
used as predictors for imputation models. 
 
Sensitivity Analyses 




to sampling) as there has been disagreement as to the appropriateness of weighting when 
using NHANES data for estimating exposure-outcome associations [158]. We conducted 
analyses using only participants with all relevant covariate information to compare with 
our results that were generated using multiply imputed data. Additionally, we conducted 
analyses using an alternative approach to account for urinary dilution. We compared the 
results from our primary model, DPHP urinary excretion rate, to a model that included 
covariate adjusted standardization of creatinine with log transformed creatinine as a 
covariate [147]. In this novel method, creatinine is first modeled as a function of measured 
variables known to affect it (i.e., race/ethnicity, age, or gender). The urinary biomarker is 
then divided by the ratio of the predicted (modeled) creatinine value to the measured 
creatinine value. Additionally, creatinine is also included in the model as a covariate to 
further account for residual confounding. 
 
Results 
 Because of varying eligibility requirements for each metabolic health outcome, the 
number of participants varied for each outcome. The amount of covariate data imputed for 
each outcome can be found in the supplemental material (Table S2.1). Table 2.1 
summarizes participant characteristics for the largest outcome subpopulation, BMI. Adults 
aged 20–50 years and 51–79 years within our largest outcome subpopulation were 
approximately 50% female, and were generally white, college educated with household 
incomes greater than $75,000 and with no history of smoking or alcohol consumption 




recommended daily values (20-34% total energy) and engaged in less than 150 minutes of 
moderate intensity physical activity a week (Table 1).  
 The geometric mean urinary DPHP excretion rates in our population for adults aged 
20-50 and 51–79 years were 0.036 and 0.026 µg/hr, respectively. Among adults aged 20-
50 years, urinary DPHP concentrations were lower among Hispanic Others, Mexican-, and 
Asian-Americans compared to Whites. Among adults aged 51-79 years, urinary DPHP 
concentrations were lower for females compared to males and Hispanic Others compared 
to Whites (Table 2.1). 
Biomarkers of diabetes risk and adiposity measures were similar for adults 20–50 
years and 51–79 years (Table 2.2). Participants in this study had normal blood glucose 
levels based on the guidelines for the clinical diagnosis of diabetes (FPG, 2-hour glucose, 
HbA1c) [158]. 
Urinary DPHP was not associated with biomarkers of diabetes risk among adults 
in our study. Multivariate analyses were used to estimate the associations between urinary 
DPHP quartiles and biomarkers of type 2 diabetes risk (FPG, HbA1c, 2hr-glucose, HOMA-
IR). The quartile ranges of urinary DPHP for each outcome in these analyses and all 
subsequent analyses can be found in the supplemental material (Table S2.2). Urinary 
DPHP showed no associations or patterns with markers of diabetes risk in all adults (Table 
S2.3). Sex, age and menopause status did not modify the association between urinary 
DPHP and markers of diabetes risk (Tables S2.5, S2.6, S2.7). We found no significant 
associations or patterns with urinary DPHP and biomarkers of diabetes risk among adults 




statistical models, we found similar associations between quartiles of urinary DPHP and 
biomarkers of diabetes risk for all adults (Table S2.8). 
Urinary DPHP was associated with higher WC, BMI, and SAD among young 
adults. Multivariate analyses were used to explore the associations between urinary DPHP 
quartiles and measures of body adiposity (WC, BMI, SAD). The urinary DPHP quartile 
ranges for each outcome in these analyses can be found in the supplemental material (Table 
S2.2). Compared to those in the first quartile, those in the fourth quartile had a 6.26 (95% 
CI: 3.66, 8.86) cm larger WC, 2.58 (95% CI: 1.18, 3.97) kg/m2 greater BMI, and 1.54 (95% 
CI: 0.84, 2.24) cm greater SAD (Table S2.4). Sex and menopause status did not modify the 
associations between urinary DPHP and markers of adiposity (Tables S2.5, S2.6), but age 
did (Table S2.7). Among younger adults, higher urinary DPHP was associated with higher 
body adiposity measures (Figure 2.1). Young adults in the third and fourth quartiles of 
DPHP had significantly higher WC (Q3: β=4.35 cm, 95% CI: 1.98, 6.72; Q4: β=9.05 cm, 
95% CI: 7.23, 10.88) compared to young adults in the first quartile. We also found positive 
associations with BMI (Q2: β=1.49 kg/m2, 95% CI: 0.38, 2.50; Q3: β=1.92 kg/m2, 95% CI: 
0.81, 3.02; Q4: β=3.88 kg/m2, 95% CI: 2.84, 4.93) and SAD (Q3: β=1.13 cm, 95% CI: 
0.38, 1.88; Q4: β=2.19 cm, 95% CI: 1.64, 2.74) among young adults (Figure 2.1). 
Furthermore, there were significant linear trends between urinary DPHP exposure and WC 
(p=<0.0001), BMI (p=<0.0001), and SAD (p=<0.0001). When we further stratified by sex, 
we see comparable effects among younger women and men (Figure S2.1). In contrast, we 
found no significant associations between urinary DPHP and body adiposity among adults 




In our sensitivity analysis, we also found positive associations between quartiles of 
urinary DPHP and body adiposity in unweighted analyses for both age groups, not just the 
younger (Table S2.9). Linear regression results using participants with complete covariate 
information were consistent with results using multiply imputed data (data not shown). In 
models with the alternative exposure measure (covariate adjusted standardization of 
creatinine plus creatinine adjustment), we found similar patterns between exposure and 
body adiposity measures with older and younger adults (Figure S2.3).  
 
Discussion  
 In this cross-sectional study, we found positive relationships between urinary 
DPHP excretion and body adiposity in adults aged 20–50 years, but not older adults (in 
weighted analyses). Neither sex nor menopausal status modified these associations. 
Urinary DPHP was not associated with any of our biomarkers of diabetes risk.  
Overall, we found no consistent pattern in the data to suggest an association 
between urinary DPHP and type 2 diabetes risk. Multiple biomarkers of diabetes risk were 
used in the analyses, including both long- and short-term measures of blood glucose. Due 
to the inherent differences in these measures, it was possible for us to find different results 
for each measure of diabetes risk. HOMA-IR, computed from an individual’s fasting 
plasma glucose and insulin levels, is more commonly used in research to assess insulin 
resistance. HbA1c is believed to be better at capturing chronic hyperglycemia, and all three 
measures, FPG, 2-hour glucose, and HbA1c, can present conflicting results regarding 




to our exclusion criteria. We excluded participants currently taking diabetes medications 
from our analyses to prevent a reduction in the estimated effect of DPHP on the outcomes. 
However, this ultimately eliminated the most susceptible study participants.  
We found consistent positive associations between urinary DPHP and our measures 
of body adiposity. Unlike BMI and WC, SAD is less commonly used in studies as a 
measure of obesity or adiposity. However, all three have been shown to be associated with 
obesity-related biomarkers and metabolic health [160-162].  
Our stratified analyses using sample weights and strata and cluster variables 
revealed that the positive associations between urinary DPHP and measures of body 
adiposity were limited to adults aged 20–50 years. Older men had approximately the same 
urinary DPHP excretion as younger men and women, yet we found no positive associations 
with body adiposity among older men. The null results could be due to changes in body 
composition associated with aging or other age-related health risks impacting weight gain 
[163]. On the other hand, unweighted regression analyses showed positive associations 
between urinary DPHP and adiposity in both younger and older adults. There is 
disagreement on whether weighted or unweighted analysis should be used for NHANES 
data in analytical epidemiology [158]. 
To date, only one other study has investigated TPHP’s role as an MDC in humans. 
Overall, Boyle et al. reported no significant associations between urinary DPHP and 
measures of adiposity in adults aged 20 and up using models with log transformed urinary 
creatinine concentrations to adjust for urine dilution. The authors classified adults as 




Urinary DPHP was positively associated with BMI in males and inversely associated in 
females [107]. We found positive associations between urinary DPHP and SAD, BMI, and 
WC in adults aged 20–50 years; the differences in our main findings could be attributed to 
our modeling of urinary DPHP as an excretion rate with urine flow data. In our sensitivity 
analyses using creatinine to adjust for urine dilution, our findings with adiposity in younger 
adults were positive but also not significant. Additionally, similar to Boyle et al., we found 
no evidence of effect measure modification by sex. 
In vitro studies show that TPHP induces adipogenesis, in both human and mouse 
preadipocytes [74, 75, 128]. Furthermore, rodent studies also report adverse metabolic 
health outcomes as a result of early life exposure to TPHP. In rats, exposure to Firemaster 
550, a commercial mixture of TPHP, and TPHP directly resulted in increased body weight 
gain and obese phenotypes regardless of sex [76, 77]. Similarly, in utero and lactational 
and neonatal exposure to TPHP increased body weight, fat mass, hepatic steatosis, 
impaired glucose homeostasis, and insulin resistance in male mice only [78, 79].  
TPHP could be impacting metabolic health by binding to and activating the nuclear 
receptor PPARγ. PPARγ plays an important role in metabolic homeostasis because of its 
role in regulating the formation and function of adipocytes and insulin sensitivity [129]. 
Studies have shown that TPHP is an efficacious activator of PPARγ and stimulates 
adipocyte formation [73-75, 128]. Adipose tissue, comprised of adipocytes, is a highly 
active endocrine and metabolic organ; both the volume and quality of adipose tissue are 
associated with risk of disease [9, 10]. As adipose tissue accumulates and outpaces the 




activate signaling pathways leading to fibrosis and inflammation, which in turn leads to 
adipose tissue dysfunction that can set the stage for insulin resistance and other metabolic 
irregularities [11].   
It is also worth noting that activation of PPARγ can also be associated with 
improved insulin sensitivity. The adipocyte-inducing and insulin-sensitizing activities of 
PPARγ are regulated separately with ligands have distinct abilities to activate each of 
PPARγ’s functions [32, 164, 165]. Our own work shows that TPHP induces the formation 
of adipocytes that are functionally distinct from adipocytes induced by rosiglitazone, a 
highly potent PPARγ agonist that is used in the treatment of type 2 diabetes [166]. Patients 
using rosiglitazone (trade name Avandia) experienced increased weight gain but decreased 
FPG, mean glucose during oral glucose tolerance test, and HbA1c [33, 34]. Indeed, 
development of selective PPARγ modulators is a strategy being used to design therapeutics 
that maximize insulin sensitization while minimizing adverse effects [167]. In this study, 
we only found associations between a urinary metabolite of TPHP and adiposity. 
 The present study has several limitations. Due to the cross-sectional nature of our 
study, the temporal relationships between exposure to the OPE and the outcomes cannot 
be determined. The use of urinary DPHP to assess TPHP exposure has limitations. First, 
urinary DPHP is an non-specific biomarker of exposure for TPHP because it is also a 
metabolite of other OPEs such as 2-ethylhexyl diphenyl phosphate (EDPHP) and resorcinol 
bis(diphenyl phosphate) [127]. Direct exposure to DPHP can occur because it is used as an 
additive in paints and coatings and has been detected in both indoor and outdoor 




to days, suggesting that TPHP is metabolized and excreted fairly rapidly from the body 
[170]. Spot urine samples show low reliability (i.e., low intraclass correlation coefficients) 
over a period of one year [135]. As changes in body adiposity occur over time, recent 
exposure may not properly reflect the influence of the OPE on the outcome. As a result, 
future studies should incorporate other exposure measures, aside from spot samples, to 
investigate the effect on adiposity. Finally, although urinary DPHP excretion rate is the 
best exposure metric because we avoid any bias associated with creatinine, there could be 
some measurement error associated with urinary flow rate since its calculation relies on 
self-reported data. 
Despite this possible measurement error, we used urinary excretion rate as our 
primary exposure measure. Variable hydration status among participants can lead to 
exposure measurement error when using uncorrected urine concentrations of chemicals. 
Traditionally, this is mitigated by creatinine correction or inclusion of creatinine as a 
predictor in the model [171]. However, creatinine can be associated with other covariates, 
such as age, sex, race, and fat-free mass or BMI. If creatinine is a common descendant of 
two or more other variables in the DAG, commonly referred to as a collider, adjusting for 
it in the model can create false, non-causal associations and bias the results [172, 173]. By 
using urine flow rate as our primary method, we avoid relying on creatinine since many of 
our covariates (race/ethnicity, sex, and age) are both risk factors for the outcomes (blood 
glucose and body adiposity) and affect creatinine. We also conducted sensitivity analyses 
using another proposed method: covariate adjusted creatinine standardization plus 




estimates were smaller in magnitude and not significant (Figure S3). Other studies have 
also used this method as a sensitivity analysis and have found results that are comparable 
to traditional creatinine correction methods [174-177]. Despite the wealth of socio-
demographic, behavioral, and dietary information in NHANES that allowed us to control 
for key variables, there may have been residual confounding and misclassification of 
covariate variables. For example, diet and physical activity are considered important and 
modifiable risk factors for metabolic health. Since TPHP is used as plasticizer, diet could 
potentially be a source of exposure, although this has yet to be studied. Diet and physical 
activity information were included in analyses based on current U.S. health guidelines 
[151, 153], but there is a lack of consensus in the literature regarding how they affect the 
outcomes. Questions remain regarding which components of diet are most consequential 
for metabolic health and how much physical activity actually reduces risk of type 2 diabetes 
and obesity [151, 178]. There can be residual confounding if diet or physical activity were 
not properly controlled in our analyses.  
 Previous studies reported changes in TPHP exposure by season with summer 
months being associated with significantly higher levels of TPHP exposure [155]. This 
could lead to confounding with adiposity measures if the latter also depend on season. We 
incorporated information into our models regarding the time of year a person’s exposure 
and outcome was measured, but it did not change the results (data not shown). Another 
strength of this study is that we explored this research question in a large study population 






 To our knowledge, this is the first epidemiologic study to investigate the 
relationship between urinary DPHP and multiple biomarkers of diabetes risk and body 
adiposity. Our analysis observed positive associations between urinary DPHP and body 
adiposity measures, particularly in younger men and women. Additional animal studies 
and epidemiological studies with repeated measures of TPHP in humans and longitudinal 
data are needed to further elucidate the role of triphenyl phosphate as an environmental 






Table 2.1. Geometric means (95% confidence interval [CI]) of urinary diphenyl phosphate 
excretion rate (µg/hr) by study population characteristic, stratified by age, within the largest 
subpopulation (those with the outcome body mass index). 
 










All Adults   0.036   0.026 
Sex       
Male 385 51.6 0.036 (0.03-0.04) 214 46.8 0.035 (0.03-0.04) 
Female 361 48.4 0.036 (0.03-0.05) 243 53.2 0.022 (0.02-0.03)* 
Race/Ethnicity       
White 317 42.5 0.040 (0.04-0.05) 199 43.5 0.029 (0.02-0.04) 
African-American 129 17.3 0.037 (0.03-0.05) 103 22.5 0.024 (0.02-0.03) 
Mexican-American 103 13.8 0.031 (0.03-0.04)* 56 12.3 0.024 (0.02-0.03) 
Asian-American 91 12.2 0.029 (0.02-0.04)* 54 11.8 0.018 (0.01-0.03) 
Multi-racial 28 3.8 0.036 (0.02-0.06) 7 1.5 0.016 (0.01-0.03) 
Hispanic Other 78 10.5 0.028 (0.02-0.04)* 38 8.3 0.02 (0.02-0.024)* 
Education       
< High School 111 14.9 0.035 (0.03-0.04) 103 22.5 0.031 (0.02-0.05) 
High School 162 21.7 0.038 (0.03-0.05) 100 21.9 0.025 (0.02-0.03) 
Some College 473 63.4 0.037 (0.03-0.04) 254 55.6 0.027 (0.02-0.04) 
Income       
< $20 K 105 15.4 0.030 (0.02-0.04) 102 24.8 0.029 (0.02-0.04) 
$20 K— <35 K 124 18.2 0.041 (0.03-0.05) 65 15.8 0.025 (0.02-0.03) 
$35K— <75 K 212 31.1 0.033 (0.03-0.04) 121 29.4 0.021 (0.01-0.03) 
>$75K 240 35.2 0.039 (0.03-0.05) 123 29.9 0.032 (0.02-0.04) 
Alcoholic 
Drinks/Week 
      
None 152 20.4 0.034 (0.03-0.04) 173 37.9 0.029 (0.02-0.04) 
<1 344 46.1 0.038 (0.03-0.05) 122 26.7 0.021 (0.01-0.03) 
1— <4 202 27.1 0.037 (0.03-0.05) 103 22.5 0.027 (0.02-0.04) 
4— <8 48 6.4 0.033 (0.02-0.05) 59 12.9 0.034 (0.03-0.04) 
Smoking       
Ever 121 16.2 0.039 (0.03-0.05) 139 30.4 0.024 (0.02-0.04) 
Current 174 23.3 0.030 (0.03-0.06) 96 21.0 0.022 (0.02-0.03) 




      
<150 389 52.1 0.039 (0.03-0.04) 337 73.6 0.027 (0.02-0.04) 
150 – <300 129 17.3 0.033 (0.03-0.04) 46 10.0 0.026 (0.02-0.043 
 300 228 30.6 0.035 (0.03-0.04) 74 16.2 0.030 (0.02-0.04) 
Total Fat Intake 
(% total energy) 
      
< 20 15 2.4 0.048 (0.02-0.09) 9 2.3 0.025 (0.01-0.05) 
20 - <35 326 52.2 0.037 (0.03-0.04) 212 53.9 0.028 (0.02-0.03) 
 35 284 45.4 0.036 (0.03-0.04) 172 43.8 0.024 (0.02-0.03) 




*Statistically significant differences in urinary DPHP by characteristic within each age 
group conducted using multivariable linear regression to compare categorical mean 
estimates (p<0.05)  
aTotal numbers of subjects per variable do not equal 746 or 457 respectively due to missing 
subjects. See text Statistical Analyses section. 
bUrinary excretion flow rate diphenyl phosphate is the DPHP concentration multiplied by 
the urinary flow rate. Geometric means and 95% confidence intervals were calculated by 











A1ca (%) 2-hour glucosea 
(mg/dL) 




20-50 years 96.0 (10.5) 5.30 (0.4) 100 (44.8) 1.88 (2.6) 99.6 (17.1) 28.7 (7.5) 21.8 (4.5) 
51-79 years 101.0 (15.0) 5.60 (0.6) 119 (30.4) 1.91 (3.3) 96.3  (15.2) 28.6 (6.4) 22.9 (4.2) 
a Medians and standard deviations used for variables that are not normally distributed 








Table 2.3. Percent change (95% confidence intervals) in type 2 diabetes measure (compared to Q1) from multivariate analyses 
stratified by age between urinary excretion rate diphenyl phosphate and log-transformed (ln) fasting plasma glucose (FPG), 










0.90 0.62 0.19 0.09 
Urinary 
DPHP 
N  N  N  N  
Q1c 67  145  61  62  
Q2 77 2.0 (-1.0, 4.1) 174 0.37 (-1.0, 2.0) 71 -0.01 (-10.3, 11.5) 75 -15.6 (-32.0, 7.3) 
Q3 88 1.0 (-2.0, 3.0) 200 0.28 (-1.0, 2.0) 82 -6.4 (-14.7, 2.7) 84 17.4 (-10.4, 52.5) 
Q4 103 1.0 (-2.0, 4.1) 209 0.51 (-1.0, 2.0) 89 3.8 (-7.3, 16.2) 93 9.4 (-12.2, 36.3) 
51-79 years 






0.73 0.97 0.55 0.87 
Urinary 
DPHP 
N  N  N  N  
Q1c 73  149  64  68  
Q2 62 -1.0 (-6.8, 6.2) 121 1.0 (-2.0, 5.1) 55 -4.9 (-15.6, 8.3) 55 0.22 (-22.9, 29.7) 
Q3 52 -3.9 (-11.3, 4.1) 94 -2.0 (-3.0, 2.0) 44 -16.5 (-30.2, -1.0) 47 -18.4 (-47.8, 28.4) 
Q4 37 -1.0 (-8.6, 6.2) 85 1.0 (-2.0, 3.0) 36 -6.8 (-20.5, 8.3) 37 2.2 (-26.7, 43.3) 
aAnalyses adjusted for adjusted age, gender, race/ethnicity, income, education status, physical activity, percent total energy from 
fat, 6-month time period of examination, alcohol intake, and smoking  
bLinear trend is effect estimate and p value (p<0.05)  






Figure 2.1. Effect estimates and 95% confidence interval for adults aged 20-50 years  for 
multivariate analyses between urinary excretion rate diphenyl phosphate (DPHP; µg/hr) 
and waist circumference (WC; cm), body mass index (BMI; kg/m2), and sagittal 
abdominal diameter (SAD; cm). Analyses adjusted for adjusted age, gender, 
race/ethnicity, income, education status, physical activity, percent total energy from fat, 
6-month time period of examination, alcohol intake, and smoking. WC N=736; BMI N= 







Figure 2.2. Effect estimates and 95% confidence interval for adults aged 51-79 years for 
multivariate analyses between urinary excretion rate diphenyl phosphate (DPHP; µg/hr) 
and waist circumference (WC; cm), body mass index (BMI; kg/m2), and sagittal abdominal 
diameter (SAD; cm). Analyses adjusted for adjusted age, gender, race/ethnicity, income, 
education status, physical activity, percent total energy from fat, 6-month time period of 





























 N=559 N=1177 N=502 N=521 N=1184 N=1203 N=1173 




























Q1 4e-4 -0.0120 4e-4-0.0149 4e-4-0.0117 4e-4-0.012 4e-4-0.01493 4e-4-0.01493 
4e-4 – 
0.01493 





Q3 0.00263-0.0613 0.0306-0.0653 0.026-0.065 0.0265-0.0629 0.0305-0.0645 0.0305-0.065 
0.0305-
0.0645 










Table S2.3. Percent change in type 2 diabetes measure compared to Q1. Effect estimates from multivariate analyses between 
urinary excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and log-transformed fasting plasma glucose (FPG), A1c, 2-
hour glucose, and homeostatic modeling assessment for insulin resistance (HOMA-IR) for all adults a.  
 





0.71 0.62 0.50 0.32 
Urinary 
DPHP 
N  N  N  N 
 
Q1c 140  294  125  130  
Q2 139 -0.4 (-3.9, 4.1) 295 1.0 (-1.0, 2.0) 126 -2.0 (-9.5, 5.1) 130 -13.1 (-30.9, 9.4) 
Q3 140 -2.0 (-5.8, 2.0) 294 0.10 (-2.0, 2.0) 126 -10.4 (-17.3, -3.0) 131 -3.9 (-26.7, 27.1) 
Q4 140 -0.01 (-0.05, 0.03) 294 1.0 (-1.0, 2.0) 125 -1.0 (-7.7, 6.2) 130 2.0 (-19.7, 31.0) 
aAnalyses adjusted for adjusted age, gender, race/ethnicity, income, education status, physical activity, percent total energy from 
fat, 6-month time period of examination, alcohol intake, and smoking  
b Linear trend is effect estimate and p value (p<0.05)  






Table S2.4. Effect estimates from multivariate analyses between urinary excretion rate 
diphenyl phosphate (Urinary DPHP; µg/hr) and waist circumference (WC), body mass 
index (BMI), and sagittal abdominal diameter for all adults (SAD) a. 
 
 WC (cm) BMI (kg/m2) SAD (cm) 
P for 
trendb 
<.0001 <.0001 <.0001 
Urinary 
DPHP 
N  N  N  
Q1c 296  301  293  
Q2 296 1.01 (-1.93, 3.97) 300 0.56 (-0.67, 1.79) 293 0.35 (-0.43, 1.13) 
Q3 296 1.97 (-0.65, 4.59) 301 0.69 (-0.65, 2.03) 294 0.57 (-0.18, 1.32) 
Q4 296 6.26 (3.66, 8.86) 301 2.58 (1.18. 3.97) 293 1.54 (0.84, 2.24) 
a Analyses adjusted for adjusted age, gender, race/ethnicity, income, education status, 
physical activity, percent total energy from fat, 6-month time period of examination, 
alcohol intake, and smoking 
b Linear trend is effect estimate and p value (p<0.05)  





Table S2.5. Effect estimates and p-values from multivariate analyses between urinary 
excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist circumference (WC), 
body mass index (BMI), sagittal abdominal diameter (SAD), and log-transformed (ln) 
fasting plasma glucose (FPG), A1c, 2-hour glucose, and homeostatic modeling assessment 
for insulin resistance (HOMA-IR) for all adults. Interaction between sex and urinary DPHP 
assessed using product interaction terms.  
 




























































a Percent change in outcome compared to Q1 






Table S2.6. Effect estimates and p-values from multivariate analyses between urinary 
excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist circumference (WC), 
body mass index (BMI), sagittal abdominal diameter (SAD), and log-transformed (ln) 
fasting plasma glucose (FPG), A1c, 2-hour glucose, and homeostatic modeling assessment 
for insulin resistance (HOMA-IR) for all adults. Interaction between menopause and 






























































a Percent change in outcome compared to Q1 






Table S2.7. Effect estimates and p-values from multivariate analyses between urinary 
excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist circumference (WC), 
body mass index (BMI), sagittal abdominal diameter (SAD), and log-transformed (ln) 
fasting plasma glucose (FPG), A1c, 2-hour glucose, and homeostatic modeling assessment 
for insulin resistance (HOMA-IR) for all adults. Interaction between age and urinary DPHP 






























































a Percent change in outcome compared to Q1 








Table S2.8. Percent change in type 2 diabetes measure compared to Q1. Unweighted effect estimates and 95% confidence interval 
from multivariate analyses between urinary excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and log-transformed (ln) 
fasting plasma glucose (FPG), A1c, 2-hour glucose, and homeostatic modeling assessment for insulin resistance (HOMA-IR) 
for adults aged 20–50 years and 51–79 years.  
 
20–50 years 






0.85 0.28 0.57 0.09 
Urinary 
DPHP 
N  N  N  N  
Q1b 67  145  61  62  
Q2 77 1.0 (-2.0, 5.1) 174 -0.4 (-2.0, 1.0) 71 -3.0 (-13.9, 7.3) 75 -6.8 (-28.1, 20.9) 
Q3 88 1.0 (-2.0, 4.1) 200 0.4 (-1.0, 2.0) 82 -7.7 (-16.5, 2.0) 84 6.2 (-18.1, 52.2) 
Q4 103 1.0 (-2.0, 4.1) 209 0.5 (-1.0, 2.0) 89 -1.0 (-9.5, 9.4) 93 3.0 (-20.5, 32.3) 
51–79 years 
 






0.85 0.87 0.55 0.86 
Urinary 
DPHP 
N  N  N  N  
Q1b 73  149  64  68  
Q2 62 2.0 (-3.0, 7.2) 121 1.4 (-1.0, 4.1) 55 -2.0 (-14.8, 11.6) 55 20.9 (-9.5, 61.6) 
Q3 52 -2.0 (-6.8, 3.0) 94 -2.0 (-2.0, 2.0) 44 -12.2 (-23.7, 1.0) 47 11.6 (-17.3, 50.7) 
Q4 37 1.0 (-4.9, 7.3) 85 1.0 (-2.0, 3.0) 36 -1.0 (-14.8, 15.0) 37 39.1 (0.1, 91.6) 
a Analyses adjusted for adjusted age, gender, race/ethnicity, income, education status, physical activity, percent total energy  
from fat, 6-month time period of examination, alcohol intake, and smoking. 
b Linear trend is effect estimate and p value (p<0.05)  





Table S2.9. Unweighted effect estimates from multivariate analyses between urinary 
excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist circumference (WC), 
body mass index (BMI), and sagittal abdominal diameter for all adults (SAD). Analyses 
adjusted for adjusted age, gender, race/ethnicity, income, education status, physical 




 WC (cm) BMI (kg/m2) SAD (cm) 
P for trendc 0.0001 <0.001 0.001 
Urinary 
DPHP 
N  N  N  
Q1b 147  149  146  
Q2 175 1.99 (-1.42, 5.39) 176 1.24 (-0.28, 2.76) 171 0.31 (-0.59, 1.21) 
Q3 201 3.96 (0.65, 7.27) 206 1.96 (0.49 3.42) 199 0.89 (-0.01, 0.17) 
Q4 213 6.33 (3.06, 9.61) 215 3.11 (1.66, 4.57) 210 1.43 (0.57, 2.29) 
51-79 years 
 WC (cm) BMI (kg/m2) SAD (cm) 
P for trendc 0.01 0.01 0.002 
Urinary 
DPHP 
N  N  N  
Q1b 149  152  147  
Q2 121 0.82 (-2.61, 0.64) 124 0.07 (-1.34, 1.49) 122 0.55 (-0.38, 1.48) 
Q3 95 2.27 (-1.45, 6.00) 95 0.33 (-1.22, 1.89) 95 0.84 (-0.18, 1.85) 
Q4 83 5.17 (1.22, 9.11) 86 1.91 (0.29 3.53) 83 1.73 (0.66, 2.80) 
aAnalyses adjusted age, race/ethnicity, income, education status, physical activity, total fat 
intake, and alcohol intake. 
bLinear trend is effect estimate and p value (p<0.05)  





Figure S2.1. Effect estimates and 95% confidence interval from multivariate analyses 
between urinary excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist 
circumference (WC; cm), body mass index (BMI; kg/m2), and sagittal abdominal diameter 
(SAD; cm) in women and men aged 20-50 years. Analyses adjusted for adjusted age, 
race/ethnicity, income, education status, physical activity, percent total energy from fat, 6-
month time period of examination, alcohol intake, and smoking. Women: WC N=355; BMI 









Figure S2.2. Effect estimates and 95% confidence interval from multivariate analyses 
between urinary excretion rate diphenyl phosphate (Urinary DPHP; µg/hr) and waist 
circumference (WC; cm), body mass index (BMI; kg/m2), and sagittal abdominal diameter 
(SAD; cm) in men and women aged 51-79 years. Analyses adjusted for adjusted age, 
race/ethnicity, income, education status, physical activity, percent total energy from fat, 6-
month time period of examination, alcohol intake, and smoking. Women: WC N=237; BMI 








Figure S2.3. Effect estimates and 95% confidence interval from multivariate analyses 
between covariate adjusted standardization of creatinine plus creatinine adjustment 
diphenyl phosphate (DPHP; µg/hr) and waist circumference (WC; cm), body mass index 
(BMI; kg/m2), and sagittal abdominal diameter (SAD; cm) in all adults. Analyses adjusted 
for adjusted age, gender, race/ethnicity, income, education status, physical activity, percent 
total energy from fat, 6-month time period of examination, alcohol intake, and smoking. 
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Background: Humans are exposed to a complex mixture of environmental chemicals that 
impact bone and metabolic health, and traditional exposure assessments struggle to capture 
these exposure scenarios. Peroxisome proliferator activated receptor-gamma (PPARγ) is 
an essential regulator of metabolic and bone homeostasis, and its inappropriate activation 
by environmental chemicals can set the stage for adverse health effects. Here, we present 
the development of the Serum PPARγ Activity Assay (SPAA), a simple and cost-effective 
method to measure total ligand activity in small volumes of serum. 
  
Methods: First, we determined essential components of the bioassay. Cos-7 cells were 
transfected with combinations of expression vectors for human PPARγ and RXRα, the 
obligate DNA-binding partner of PPARγ, along with PPRE (DR1)-driven luciferase and 
control eGFP reporter constructs. Transfected cells were treated with rosiglitazone, a 
synthetic PPARγ ligand and/or LG100268, a synthetic RXR ligand, to characterize the dose 
response and determine the simplest and most efficacious format. Following optimization 
of the bioassay, we assessed the cumulative activation of PPARγ by ligands in serum from 
mice treated with a PPARγ ligand and commercial human serum samples.  
 
Results: Cos-7 cells endogenously express sufficient RXR to support efficacious activation 
of transfected PPARγ. Co-transfection of an RXR expression vector with the PPARγ 
expression vector did not increase PPRE transcriptional activity induced by rosiglitazone. 




presence of transfected PPARγ, and co-treatment with an RXR ligand reduced 
rosiglitazone-induced PPRE transcriptional activity. Therefore, the final bioassay protocol 
consists of transfecting Cos-7 cells with a PPARγ expression vector along with the reporter 
vectors, applying rosiglitazone standards and/or 10 µL of serum, and measuring 
luminescence and fluorescence after a 24 hr incubation. Sera from mice dosed with 
rosiglitazone induced PPRE transcriptional activity in the SPAA in a dose-dependent and 
PPARγ-dependent manner. Additionally, human serum from commercial sources induced 
a range of PPRE transcriptional activities in a PPARγ-dependent manner, demonstrating 
the ability of the bioassay to detect potentially low levels of ligands.  
 
Conclusions: The SPAA can reliably measure total PPRE transcriptional activity in small 
volumes of serum. This system provides a sensitive, straightforward assay that can be 






Historically, the rising incidence in obesity has been attributed to genetic 
background, changes in diet and the modern lifestyle, yet these factors fail to fully explain 
the rapid onset of the epidemic [179]. The commercial chemical registry instituted by the 
Toxic Substances Control Act currently consists of 84,000 chemicals [180]. At a minimum, 
25,000 of these chemicals are actively used in commercial products today [181]. Exposures 
to these chemicals arise in the outdoor environment from industrial releases and the indoor 
environment from use of consumer goods. Widespread exposure to low doses of a number 
of these metabolism disrupting chemicals (MDCs), a class of endocrine disrupting 
chemicals (EDCs), has been linked to obesity due to their abilities to inappropriately 
activate fat-forming pathways and enhance weight gain through white fat accumulation 
[5]. 
The search for MDCs that act on adipose tissue has focused on identifying ligands 
for the nuclear receptor peroxisome proliferator activated receptor gamma (PPARγ). 
PPARγ regulates white, brown, and brite (brown-in-white) adipogenesis, mature adipocyte 
maintenance, function and survival, and insulin sensitivity [16, 17, 182], as well as the 
balance of adipogenesis and osteogenesis [19, 20]. PPARγ is a ligand-activated 
transcription factor that binds to the PPAR response element (PPRE, 5’-
CAAAACAGGTCANAGGTCA-3’) heterodimerized with the retinoid x receptors (RXR) 
to regulate gene transcription [21]. Activation of PPARγ by exogenous ligands induces 
adipogenesis [183] and increases subcutaneous and abdominal adiposity [34, 184]. 




marrow adiposity and reduced bone quality in mouse models [186, 187] and in humans 
[33, 188]. 
 PPARγ ligands include structurally diverse endogenous and exogenous (natural and 
synthetic) ligands. Prostaglandins are known fatty acid-derived endogenous PPARγ 
ligands derived from the lipid membrane [26]. Exogenous ligands include naturally-
occurring, therapeutic, and environmental chemicals. Natural products, such as foods and 
medicinal plants, containing PPARγ activating constituents have been investigated for their 
potential therapeutic potential [189]. Drugs of the thiazolidinedione class (e.g. 
rosiglitazone, Avandia®) are highly potent PPARγ agonists that upregulate PPARγ’s 
insulin sensitizing functions [32, 183]. While thiazolidinediones activate PPARγ with 
potencies in the mid-nanomolar range, natural PPARγ ligands and endogenous compounds 
have micromolar potencies [183, 189, 190].  
Environmental PPARγ ligands are a growing class of MDCs, including phthalates, 
organotins, brominated flame retardants, organophosphate flame retardants and polycyclic 
aromatic musks, which induce adipogenesis [52, 55, 61, 67, 74, 191, 192]. Environmental 
PPARγ ligands have potencies ranging from nanomolar (i.e., organotins) to micromolar 
(i.e., phthalates) [55, 61, 74]. In addition to inducing adipocyte differentiation in vitro, at 
least phthalates [64], organotins [193, 194], and organophosphate esters [77] also increase 
adiposity in vivo. Additionally, growing evidence suggests that reduced bone quality is an 
adverse health effect of environmental PPARγ ligands [60, 195, 196]. 
  Detection of environmental PPARγ ligands in human biological samples [155, 197-




mixture of both environmental and therapeutic PPARγ ligands, and components of these 
mixtures — full agonists, partial agonists and competitive antagonists — act cumulatively 
to activate PPARγ in a predictable manner [201]. Nuclear receptor-dependent bioassays 
can provide inexpensive and rapid assessments of the biological activities of ligand 
mixtures. Originally developed to measure the aryl hydrocarbon receptor activity of 
polyhalogenated aromatic hydrocarbons [202], chemical-activated gene luciferase 
(CALUX) bioassays have been adapted and validated for use as tools to assess exposure to 
environmental ligands, including aryl hydrocarbon receptor, estrogen receptor and PPARγ 
ligands [203-209]. Here, we have developed a bioassay to quantify total PPARγ ligand 
activity in serum samples, using a rodent model and human serum samples from 
commercial sources. As PPARγ forms an obligate, permissive heterodimer with RXR, and 
ligands for either receptor can lead to signaling [210], we paid careful attention to the role 
of both receptors. 
 
Materials and Methods 
Materials Rosiglitazone (cat. #71740) was from Cayman Chemical (Ann Arbor, 
MI). DMSO (in vitro, cat. #AB03091) was from American Bioanalytical (Natick, MA). 
LG100268 (cat. #SML0279), T0070907 (cat. #T8703), DMSO (in vivo, cat. #D1435), and 
carboxymethylcellulose (cat. #C9481) were from Sigma-Aldrich (St. Louis, MO). HX531 
(cat. #3912) was from Tocris Bioscience (Bristol, UK). All other reagents were from 




Animal Studies Animal studies were approved by the Institutional Animal Care and 
Use Committee at Boston University and performed in an American Association for the 
Accreditation of Laboratory Animal Care accredited facility (Animal Welfare Assurance 
Number: A3316-01). Care was taken to minimize distress. Nine-week-old, female, 
C57BL/6J mice (RRID:IMSR_JAX:000664, Jackson Laboratories, Bar Harbor, ME) were 
treated by oral gavage (10 µL/g) with vehicle (Vh, 1% carboxymethylcellulose, 0.1% 
DMSO), or rosiglitazone (0.1, 1, 10, 100 mg/kg). One hour after gavage, mice were 
euthanized, and blood was collected via cardiac puncture. This time was chosen as it is the 
point of maximum serum concentrations following oral administration in humans [211, 
212]. Serum was separated and frozen at -80°C. 
Human Sera Samples Human AB serum samples were purchased from commercial 
sources (Atlanta Biologicals, Flowery Branch, GA; Corning Cellgro, Tewksbury, MA; 
Gemini Bio-products, West Sacramento, CA; MP Biomedicals, Santa Ana, CA; Sigma-
Aldrich, St. Louis, MO). These sera were collected in the United States and were from 
men. 
Reporter Assays Cos-7 cells (RRID: CVCL_0224, CRL-1651, ATCC, Manassas, 
VA) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Corning Cellgro, 
Tewskbury, MA) with 5% fetal bovine serum (FBS), amphotericin 
B/penicillin/streptomycin, and L-glutamine at 37°C and 5% CO2 atmosphere. Cells were 
plated in 96-well plates in antibiotic free media and transiently transfected with expression 
vectors, individually or in combination, containing human PPARG1 (provided by V.K. 




MA) [182] with PPRE x3-TK-luc (plasmid 1015; Addgene) [214] and CMV-eGFP 
(mammalian expression vector for expression of green fluorescent protein) (from our 
laboratory) reporter constructs. The sequence of the PPRE is 5’-
GTCGACAGGGGACCAGGACAAAGGTCACGTTCGGGAGTCGAC-3’). Transfected 
cultures were incubated overnight, and the media was replaced. Naïve wells were 
transfected with the reporter constructs alone and an empty pcDNA 3.1 plasmid (in 
proportion to the expression vectors) and left untreated. For chemical experiments, 
standard curve wells containing 100 µL of medium were treated with Vh (DMSO, 0.5%), 
rosiglitazone (10-9-10-6 M), or LG100268 (10-9-10-6 M). For serum experiments, standard 
curve wells containing 100 µL of medium received 10 µL charcoal-dextran stripped FBS 
and then were treated with Vh or standard curve chemicals. Experimental wells containing 
100 µL of medium were treated with 10 µL of mouse serum in duplicate. Human serum 
was initially titrated at volumes ranging from 0.5–50 µL to determine proper volume. In 
final human serum experiments, wells were treated with human serum in duplicate or 
quadruplicate (10 µL). Referent (ref) wells containing 100 µL of media received 10 µL of 
stripped fetal bovine serum.  In antagonist experiments, wells were treated with serum and 
then co-treated with Vh (DMSO:Ethanol, 50:50, 0.5%), T0070907 (1 µM) or HX-531 (2 
µM). After a 24hr incubation, cells were lysed using Steady-Luc Firefly HTS Reagent 
(Biotium, Freemont, CA). Luminescence (lum) and fluorescence (eGFP or flo) were 
measured using a Synergy2 multi-function plate reader (Biotek, Inc. Winooski, VT). eGFP 
values were analyzed to ensure that no treatment caused a significant decrease in 




minimize intra- and inter-experimental variation [215], as follows:  
















When subtraction of the Naïve (lum/flo) resulted in a negative number, the negative 
number was replaced with “0.” Concentrations in the plateau of the dose response curves 
were used to generate the positive controls. Rosiglitazone-treated cultures (10-7-10-6 M) 
served as the positive control for PPARγ-transfected cultures. LG100268-treated cultures 
(2x10-7 M) served as the positive control for RXR-transfected cultures. “PPRE 
transcriptional activity” is reported as the “% Maximum Activity,” relative to the positive 
control. To interpolate rosiglitazone concentrations in the mouse serum, the standard curve 
data were fit with the “log(agonist) vs. response (3 parameters)” function in conjunction 
with the “Interpolate unknowns from standard curve” function in Prism6 (GraphPad 
Software, La Jolla, CA).   
Immunoblotting Cos-7 cells were grown and maintained as described above. Whole 
cell lysates were prepared from Cos-7 cells and Cos-7 cells transfected with human 
PPARG1, human RXRA, mouse Pparg1 (plasmid 8886; Addgene), mouse Pparg2 (plasmid 
8865; Addgene) [182], mouse Rxra, mouse Rxrb, or mouse Rxrg (provided by R. M. Evans, 
Salk Institute for Biological Studies) [216]. Cos-7 cells were washed twice with PBS, lysed 
in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) and sonicated. The lysates 
were cleared by centrifugation, and the supernatants were used for protein expression 
analyses. Protein concentrations were determined by the Bradford method [58]. Total 




membrane, and incubated with primary antibody (monoclonal rabbit anti-PPARγ (cat. 
#2443, Cell Signaling Technology) or monoclonal rabbit anti-RXRα (cat. #3085, Cell 
Signaling Technology)). Immunoreactive bands were detected using HRP-conjugated 
antibodies (cat. #7074, Cell Signaling Technology) followed by enhanced 
chemiluminescence. To assess protein loading, blots were re-probed with a β-actin-specific 
antibody (cat. #A5441, Sigma-Aldrich). 
Statistical Analyses Statistical analyses were performed with Prism 6 (GraphPad 
Software). For in vivo exposures, data are reported from individual mice (n = 4-12). In 
reporter assays, serum samples were run in duplicate. Standard curves were fit with 
“log(agonist) vs. response (3 parameters)” function. Data are reported as means  standard 
errors. Student’s t-tests and ANOVA (one and two factor) combined with Tukey-Kramer, 
Sidak’s and Dunnett’s multiple comparisons tests were used to determine statistical 
significance. All analyses were performed using α = 0.05.   
  
Results 
 First, we began by determining the essential elements needed to produce a robust 
reporter system. PPARγ binds to and activates transcription at PPREs as an obligate 
heterodimer with RXRs. To develop a biomarker of total serum PPARγ ligand activity, we 
began by examining the expression of PPARγ and RXRs in Cos-7 cells, the cell model for 
the reporter assay. Cos-7 cells endogenously express PPARγ and RXRs, the receptors 
necessary to support ligand-induced PPARγ activity (column 1 (left most), Figure 3.1A-




for human PPARG1 (column 2, Figure 3.1A). The additional 30 amino acids for the 
PPARγ2 isoform (column 3 vs. 4, Figure 3.1A) retards the migration of the protein and 
comparison demonstrates that our transfection protocol specifically increases the 
expression of PPARγ1. While the specific complement of RXRs could not be identified 
because the isoforms co-migrate, it is evident that Cos-7 cells express at least one isoform 
that co-migrates with human and mouse RXRs (Figure 3.1B). 
 Next, we determined the efficacy of activation of a PPRE-driven reporter in human 
PPARG1-transfected Cos-7 cells. First, we tested if increasing the expression of PPARγ 
would improve the signal to noise ratio in the assay. Rosiglitazone, a PPARγ-specific 
ligand [183], only significantly induced transcriptional activity in human PPARG1-
transfected cells (Figure 3.2). Second, we tested the rosiglitazone dose response for 
activation of PPARγ1. Prior to normalization by the positive control, the lum/flo values 
ranged from a minimum of ≈ 1 to a maximum of ≈ 50. As expected, rosiglitazone is a 
potent and efficacious ligand in this assay (Range: 10-9-10-6 M, EC50: 1.5 x 10
-8 M)(Figure 
3.3A). We determined if the activity level could be increased further by co-transfecting 
with an RXRA expression plasmid. Co-transfection of increasing amounts of human RXRA 
expression plasmid with human PPARG1 did not increase induction of PPARγ-dependent 
transcriptional activity by rosiglitazone (Figure 3.3B).  
The transcriptional activity of PPARγ can be activated by binding of a ligand to 
PPARγ itself or by binding of a ligand to its partner RXR in some cell types [210, 217]. 
Furthermore, RXR:RXR homodimers are known to activate transcription at PPREs [218]. 




transcriptional activity we were measuring. First, LG100268, an RXR-specific ligand 
[219], potently induced PPRE-dependent reporter activity when Cos-7 cells were 
transfected with human RXRA alone (EC50= 2.7 x 10
-9 M)(Figure 3.4A). To compare the 
efficacy of transcription at the PPRE through RXR vs PPARγ, we compared the lum/flo 
values. For PPARγ, the maximal lum/flo is ≈ 50, and for RXR, the maximal lum/flo is ≈ 5. 
Therefore, PPARγ is approximately 10-fold more efficacious at activating transcription at 
this PPRE. LG100268 did not significantly induce PPRE-dependent reporter activity when 
Cos-7 cells were transfected with human PPARG1 alone (Figure 3.4B).  
According to Schulman et al (1998), co-exposures to PPARγ and RXR ligands 
induced synergistic activation of transcriptional activity at PPREs when both PPARG and 
RXR expression vectors were transfected into 3T3 L1 cells [220]. We therefore assessed 
the potential interaction of PPARγ and RXR ligands in our assay. Contrary to expectation, 
treatment of human PPARG1 transfected Cos-7 with increasing concentrations of 
LG100268 decreased rosiglitazone-induced transcriptional activity (Figure 3.4C).  
Overall, rosiglitazone induced robust PPARγ-dependent activity with the 
transfection of human PPARG1 alone. LG100268, an RXR specific ligand, did not by itself 
induce activity, as is optimal for a PPARγ transcriptional assay. However, LG100268 
reduced the rosiglitazone-induced activity, suggesting that the assay may produce an 
underestimate of the PPARγ activity if RXR ligands are present in significant quantities in 
a mixture of ligands.   
 Second, we tested the efficacy of the assay in detecting a PPARγ ligand in serum. 




potency of ligands by reducing bioavailability [221]. We therefore generated a standard 
curve for rosiglitazone in the assay (transfected with hPPARG1), adding 10 µL charcoal-
stripped FBS (Figure 3.5). As expected, rosiglitazone has a slightly higher EC50 of 6.3 x 
10-8 M compared to conditions without excess serum: EC50 =1.5 x 10
-8 M (Figure 3.3A). 
Since our goal is to measure PPARγ agonist activity in serum, we therefore used the 
standard curve in Figure 3.5 for the analyses. We define the limit of detection (LOD) here 
as the lowest concentration yielding PPRE transcriptional activity that is significantly 
different from Vh: 9 x 10-9 M (Figure 3.5B). The true LOD may be lower. As we will test 
the activity of a small amount of added serum, it is important to adjust concentrations for 
dilution. For 10 µL of serum added to 100 µL already in the well, the final concentration 
will be 1/11 (9%) of that in the serum. The LOD for rosiglitazone in added serum thus is 
approximately 10-7 M or 100 nM (see lower X axis, Figure 3.5A). 
Serum likely contains endogenous PPARγ and RXR ligands that could potentially 
swamp or mask the activity of exogenous compounds. We therefore generated serum 
samples from C57BL/6 mice one hour after exposure via oral gavage to Vh or four doses 
of rosiglitazone. The serum was applied directly to Cos-7 cells transiently transfected with 
human PPARG1. Serum from Vh-treated mice had a significantly greater PPRE 
transcriptional activity than stripped FBS (5.2 ± 0.7 vs 0.1 ± 0.1 % Maximum Activity, 
respectively; p<0.006, Student’s t-test), thus there is likely endogenous or food-derived 
agonists present in mouse serum. Serum from rosiglitazone-treated mice activated PPARγ-
dependent transcription in a dose-dependent manner. When analyzed using a Student’s t 




PPRE transcriptional activity relative to the background activity measured in Vh-treated 
mice (p < 0.02). Figure 3.6A shows the PPARγ activity associated with various doses; 
Figure 3.5 provides the rosiglitazone concentrations associated with various levels of 
PPARγ activity. Taking into account volume dilution from adding serum to the assay, we 
estimate that the 0.1 mg/kg and 1 mg/kg doses resulted in mouse serum concentration of 
55 nM (20 ng/ml) and 1.6 μM (580 ng/ml), respectively. Analysis of serum from mice 
treated with Vh or rosiglitazone on three separate days showed that the measured PPRE 
transcriptional activity was highly reproducible (Figure 3.6B). The specificity of the assay 
for PPARγ-mediated PPRE transcriptional activity is shown by the complete abrogation of 
the serum-induced activity by T0070907, a PPARγ antagonist, but not HX 531, an RXR 
antagonist (Figure 3.6C). 
Overall, the results demonstrated that PPARγ agonist activity can be detected in 
whole serum, and that the activity is dose-dependent. Therefore, in the Serum PPARγ 
Activity Assay (SPAA), we proceeded with transfecting Cos-7 cells with human PPARG1, 
the PPRE reporter, and the control reporter (CMV-eGFP). 
 Third, in order to determine the sensitivity of our bioassay to detect potentially low 
levels of PPARγ ligands in normal human serum, we examined the activation of PPARγ 
by commercial human serum samples. We began by titrating increasing amounts of human 
serum in the SPAA to determine the lowest volume that would provide a maximal signal. 
Increasing the volume of serum in the assay increased PPRE transcriptional activity (Figure 
3.7A), which was well fit by a sigmoid curve (Figure 3.7B). We choose to use 10 µL of 




transcriptional activity across the human serum samples. 
  Comparison of the serum PPARγ agonist activity in five human serum samples 
purchased from different commercial sources showed that there is a range of detectable 
activity in normal human serum, which is dependent upon the volume of serum applied 
(Figure 3.8A). The PPRE transcriptional activity induced by each sample at 10 L was 
significantly different from the activity induced in the reference wells to which charcoal 
stripped FBS was applied (Figure 3.8B). There were differences in the absolute values of 
PPRE transcriptional activity determined on different days (using distinct plasmid preps 
and cell passages) (Figure 3.8C); however, the data were highly correlated even when 
samples were run years apart. The PPRE activity in the commercial human serum sample 
was reduced to the level of the reference samples (charcoal-stripped FBS) by a PPARγ 
antagonist, demonstrating the specificity of the assay (Figure 3.8D). These data 
demonstrate the bioassay’s ability to detect a range of activities from unknown exogenous 
and endogenous ligands in small volumes of serum. 
  
Discussion 
 The growing concern with environmental chemical-mediated disruption of 
metabolism and obesity warrants improved methods to quantify exposure to environmental 
MDCs [5]. The traditional methods of assessing exposure to a single chemical fail to 
capture real world scenarios in which populations are exposed to multiple chemicals at a 
time, and these mixtures of chemicals may cause inappropriate activation of biological 




and bone homeostasis through the induction of target genes, thus making it a target for 
endocrine disruption by environmental MDCs [222].  
The Serum PPARγ Activity Assay (SPAA) was developed to measure the total 
PPARγ activity of serum samples. SPAA uses Cos-7 cells transfected with PPARγ, a 
PPRE-driven reporter, and a constitutively active control reporter. We selected human 
PPARγ1 as the most appropriate ligand target because, compared to PPARγ2, PPARγ1 is 
more broadly expressed in tissues such as adipose, liver, kidney, muscle tissue, heart, and 
spleen [23, 24]. Table 3.1 provides information on all of the reagents needed to perform 
the assay. While only serum was tested in these analyses, the assay is expected to be 
compatible with plasma, as well. However, results from serum and plasma are not 
comparable, as they contain different concentrations of proteins that could affect the 
bioavailability of ligands. Figure 3.9 presents the assay protocol. To maximize 
reproducibility and for the most accurate comparison across samples, the same plasmid 
preparation, positive control solution and serum standard should be used to analyze 
samples. Additionally, Cos-7 cells at similar passage numbers should be used. Both 
positive controls and serum standards should be run on every plate. The serum standard 
could be used as an additional normalization factor for samples run with distinct plasmid 
preparations. Last, the receptor-specificity of the serum-induced activity can be determined 
by using antagonists to PPARγ and RXR as indicated in the protocol. 
Peak serum concentrations of rosiglitazone in humans occur one hour after oral 
administration [211, 212]. The maximum serum concentration of rosiglitazone in humans 




[223]; this is approximately equivalent to 200 nM in serum or 20 nM the assay well. At 1 
hr following gavage, serum from mice dosed with 0.1 mg/kg rosiglitazone induced PPRE 
transcriptional activity equivalent to 55 nM (20 ng/mL) rosiglitazone. The activity serum 
of mice treated with 0.1 mg/kg rosiglitazone was significantly greater than the activity 
measured in serum from Vh-treated mice, and the “endogenous” activity measured in the 
serum of Vh-treated mice was significantly greater than the activity in wells treated with 
stripped serum. SPAA thus is sensitive enough to detect PPARγ ligand activity in serum at 
levels below that induced by the lowest therapeutic dose in humans.  
In vitro assays used alone or in combination with instrumental analyses, such as 
chromatography with mass spectrometry, increasingly have been used to detect and assess 
metabolic and endocrine disrupting chemicals. Previously developed CALUX bioassays 
have been used to measure PPARγ activity in food extracts, animal tissue, dust, and water 
samples [224-227]; these assays are available for purchase. However, RXR forms a 
permissive heterodimer with PPARγ and a ligand for either receptor can activate PPARγ-
dependent transcriptional activity. Thus, RXR ligands, either endogenous (9-cis retinoic 
acid) or synthetic (rexinoids LG100268), can promote the transcription of PPARγ target 
genes [210, 217]. In the PPARγ CALUX validation study, it was speculated that some of 
the induced activity could be a result of the activation of endogenous RXR. Yet, the 
researchers did not directly consider the role of RXR [207, 224]. In our bioassay, an RXR 
specific ligand does not induce significant transcription of the PPRE-driven reporter, a 
desirable feature of a PPARγ assay. It has been suggested that the combination of a PPARγ 




[210]. However, studies indicate that the permissive activity of the PPARγ - RXR 
heterodimer is largely dependent on cell type [228]. In our bioassay, increasing 
concentrations of a potent, synthetic RXR ligand reduced rosiglitazone-induced PPARγ 
transcriptional activity. However, endogenous, and natural RXR ligands (e.g. 9-cis-retinoic 
acid, phytanic acid, docosahexaenoic acid) have significantly lower potencies than 
LG100268 [229]. Thus, if RXR ligands are present in a serum sample, the activity of the 
PPARγ ligands may be underestimated; although the concentrations would have to be quite 
high for there to be a significant effect.  
SPAA provides a measure of the combined activity of mixtures of PPARγ ligands 
in whole serum: a biological measure of exposure from mixtures of full agonists, partial 
agonists and competitive antagonists. Generalized concentration addition (GCA) has been 
shown to accurately model the activity of mixtures of PPARγ ligands [201]. One possible 
use of SPAA is as a measure of exposure (biomarker of exposure) for epidemiology studies, 
particularly if combined with effect directed analysis to determine which mixture 
components are responsible for total activity [230, 231]. Alternatively, a combination of 
targeted instrumental analysis and GCA would yield an estimate of explained PPARγ 
activity that could be compared with total measured activity. For applications in 
epidemiological assessments, SPAA requires a very small volume of serum for testing (3 
by 10 L samples). Furthermore, this assay is cost effective and does not require any 
specialized equipment; most of the research materials can be found in a standard cell 
culture laboratory.  




metabolic and bone health effects. Analysis of the distribution of serum-induced PPRE 
transcriptional activities could reveal the potential for exposure to environmental ligands. 
A normal distribution would suggest that the activity is largely derived from endogenous 
ligands, while a right-skewed distribution could indicate an environmental exposure or a 
therapeutic exposure. Identification of the chemical source of the activation would then be 
needed. White adipogenic, brite/brown adipogenic, insulin sensitizing and bone 
suppressing activities of PPARγ are regulated separately through differential post-
translational modifications [32] and co-regulator recruitment [38], with ligands having 
distinct abilities to activate these PPARγ functions. Thus, the glitazone class of T2DM 
therapeutics (e.g., rosiglitazone and pioglitazone) activates PPARγ, stimulates brite 
adipocyte differentiation and increases insulin sensitivity [32], but improvement in 
metabolic health comes with significant side effects, including fat accumulation, 
hemodilution, cardiac hypertrophy and bone loss. Not surprisingly, these adverse effects 
also are mediated by PPARγ. We have shown that environmental ligands cause PPARγ to 
act in a biologically distinct manner. Because these ligands cannot trigger PPARγ to recruit 
the same coregulators they favor PPARγ’s ability to generate white adipocytes and to 
suppress bone formation [166, 232].  
 
Conclusions 
A goal of our study was to develop an assay that can be reproduced in any cell 
culture laboratory. All the cells and reagents to perform this assay are publicly available, 




from this study lay the foundation for future work on the use of biomarkers of PPARγ 
ligand exposure that incorporate mixture effects. Our simple and cost-effective assay is 
both sensitive and specific to PPARγ ligands, including those present in whole serum 
samples. While this study did not characterize the components in serum that were driving 
activity, future work will investigate environmental chemical contributors to activity in a 






Table 3.1. Reagents to perform the Serum PPARγ Activity Assay. 
Reagents and Supplies 
Cos-7 cells (RRID:CVCL_0224, CRL-1651, ATCC) 
Maintenance media: Dulbecco's Modified Eagle's Medium (DMEM) (Corning 
Cellgro, Tewskbury, MA) with 5% fetal bovine serum (FBS), amphotericin 
B/penicillin/streptomycin, and L-glutamine  
96-Well White-sided Clear Bottom Plates (cat. #: 07-200-566; Corning)  
Plasmids:  
human PPARG1 [213] or mouse Pparg1 (plasmid 8886; Addgene)a 
PPRE-3x-Tk (plasmid 1015; Addgene) 
pcDNA (plasmid 20011; Addgene) 
CMV-eGFP (plasmid 11153; Addgene)b 
Lipofectamine 2000 Transfection Reagent (cat. #: 11668019; Thermo Fisher 
Scientific) 
Opti-MEM Reduced Serum Media (cat. #: 31985062; Thermo Fisher Scientific) 
Charcoal/Dextran stripped FBS (cat. #: F6765, Sigma) 
Rosiglitazone (cat. #: 71740; Cayman Chemical) 
T0070907 (cat. #: T8703; Sigma) 
Vehicle solvent mix (50% Ethanol (cat. #: 04-355-453, Fisher Scientific): 50% 
Dimethyl sulfoxide (cat. #: AB03091; American Bioanalytical) 
Commercial Human Serum Standard (cat. #: 100-512, Gemini Bio-Products) 
Steady-Luc Firefly HTS Assay (cat. #: 30028-L3; Biotium) 
a We used human PPARγ1 provided by V.K. Chatterjee. 






Figure 3.1. Cos-7 cells endogenously express PPARγ1 (A) and RXRs (B), proteins 
necessary for PPARγ to activate transcription. Whole cell lysates were prepared from Cos-
7 cells and Cos-7 cells transfected with (A) mouse Pparg1, mouse Pparg2, human 
PPARG1 expression vectors, or (B) human RXRA, mouse Rxra, mouse Rxrb, mouse Rxrg 










Figure 3.2. Overexpression of PPARγ significantly increases transcriptional response to 
rosiglitazone. Cos-7 cells were transfected with reporter plasmids (PPRE-luciferase 
reporter, CMV-GFP reporter) and empty pcDNA 3.1 or a mouse Pparg2 expression vector. 
Cells then were treated with Vh (0.5% DMSO) or rosiglitazone (as indicated). 
Luminescence and fluorescence were measured after 24 hrs. Data are reported as mean ± 
standard error (N = 7 independent transfections). Statistical analyses indicated in the box 








Figure 3.3. Overexpression of human PPARγ1 alone is sufficient to support robust PPARγ 
transcriptional activity. Cos-7 cells were transfected with reporter plasmids (PPRE-
luciferase reporter, CMV-GFP reporter) and a human PPARG1 expression vector (A) or 
human PPARG1 and human RXRA expression vectors (B). Cells then were treated with Vh 
(0.5% DMSO, shown as 10-11 M) or rosiglitazone (10-10- 2 x 10-6 M).  Luminescence and 
fluorescence were measured after 24 hrs. Data were calculated as described in the Methods. 
Dose response data are reported as mean ± standard error (N = 3-4 independent 
transfections). Data were fit with a 3-parameter sigmoid equation. * Significantly different 







Figure 3.4. RXR ligands do not significantly activate PPARγ, but reduce rosiglitazone-
induced, PPRE-dependent transcriptional activity. Cos-7 cells were transfected with 
reporter plasmids (PPRE-luciferase reporter, CMV-GFP reporter) and a human RXRA 
expression vector (A) or a human PPARG1 expression vector (B-C).  Cells were treated 
with Vh (0.5% DMSO, reported as 10-11 M), rosiglitazone (10-10-2 x 10-6 M), and/or 
LG100268 (10-10- 2 x 10-6 M). Luminescence and fluorescence were measured after 24 hrs. 
Data were calculated as described in the Methods. Data are reported as mean ± standard 










Figure 3.5. Standard curve for rosiglitazone in the Serum PPARγ Activity Assay with 
added serum. Cos-7 cells were transfected with reporter plasmids (PPRE-luciferase 
reporter, CMV-GFP reporter) and a human PPARG1 expression vector. Charcoal stripped 
serum (10 μl) was added to each well and then the wells were treated with Vh (0.5% 
DMSO, shown as 10-11 M) or rosiglitazone (10-10 - 2 x 10-6 M), in duplicate. Luminescence 
and fluorescence were measured after 24 hrs. Data were calculated as described in the 
Methods. Data were fit with a 3-parameter sigmoid equation. (A) Standard curve used to 
calculate mouse serum rosiglitazone concentrations. The upper X axis indicates the 
concentrations of rosiglitazone in the total volume in the assay well (10-10-2 x 10-6 M). The 
lower X axis indicates the concentrations of rosiglitazone in the volume of excess serum 
added to the well (10-9- 2 x 10-5 M). (B) Compilation of standard curves performed between 
2016 and 2019. Data are reported as mean ± standard error (N = 29 independent 







Figure 3.6. Serum PPARγ Activity can be detected in whole serum from rosiglitazone-
treated mice in a dose-dependent manner. Sera were generated from nine-week-old, 
female, C57BL/6J mice were treated by oral gavage with Vh (1% carboxymethylcellulose, 
0.1% DMSO) or rosiglitazone (0.1, 1, 10, 100 mg/kg) and euthanized after 1 hr. Sera were 
analyzed in Cos-7 cells transfected with reporter plasmids (PPRE-luciferase reporter, 
CMV-GFP reporter) and human PPARG1. Experimental wells were treated with 10 µL 
mouse serum, in duplicate. Luminescence and fluorescence were measured after 24 hrs. 
Data were calculated as described in the Methods and were calculated relative to the 
standard curve shown in Figure 3.5. (A) Dose response of serum PPRE transcriptional 
activity. All mice were treated on the same day. (B) Reproducibility assessment. Mice were 
treated on three different days, with independently prepared dose solutions. Mice from each 
experiment are indicated by different symbols. For A and B, individual data are plotted 
with the mean indicated by a line. Different letters indicate group means that differed 
significantly, while groups with the same letter did not differ significantly (p<0.05, 
ANOVA, Tukey). (C) To test for receptor specificity, wells treated with serum from mice 
that were exposed to Vh or to 1 mg/kg rosiglitazone were co-treated with Vh (0.5% 
DMSO:Ethanol), PPARγ antagonist (T0070907, 1µM) or RXR antagonist (HX531, 2 µM). 
For C, data are presented as means ± standard error from all mice in the treatment group. 









Figure 3.7. Determination of optimal serum volume in the SPAA. Cos-7 cells were 
transfected, and control wells were treated as described in Figure 3.5. Experimental wells 
were treated with 0.5–50 µL of serum. Luminescence and fluorescence were measured 
after 24 hrs. Data were calculated as described in the Methods. (A) PPRE transcriptional 
activity measured in different volumes of serum (Gemini). Different letters indicate group 
means that differed significantly, while groups with the same letter did not differ 
significantly (p<0.05, ANOVA, Tukey). (B) Dose response fit of PPRE transcriptional 
activity measured in different volumes of serum. Dose response data were fit with a 3-
parameter sigmoid equation. Data are reported as mean ± standard error (N = 3 







Figure 3.8. Commercial human serum samples from different sources have distinct PPRE 
transcriptional activity. Cos-7 cells were transfected with human PPARG1 and treated 
with Vh or rosiglitazone standards as described in Figure 3.5. Experimental wells were 
treated with 0.2-20 µL human serum. Luminescence and fluorescence were measured 
after 24 hrs. Data were calculated as described in the Methods. (A) PPRE transcriptional 
activity in different volumes of commercial human serum samples. Volume response data 
were fit with a 3-parameter sigmoid equation. (B) Comparison of PPRE transcriptional 
activity induced by 10 µL of commercial human serum samples. “Ref” refers wells that 
received 10 µL of stripped fetal bovine serum. Data are reported as mean ± standard error 
(N = 7 independent transfections; 4 runs in 2017 and 3 run in 2019). Different letters 
indicate group means that differed significantly, while groups with the same letter did not 
differ significantly (p<0.05, ANOVA, Tukey). (C) Correlation analysis of assay results 
from 2017 and 2019. (D) To test for receptor specificity, serum-treated wells were co-
treated with Vh (0.5% DMSO:Ethanol) or PPARγ antagonist (T0070907, 1µM). Data are 
presented as means ± standard error from all human serum samples (N = 6) or 4 
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Background: Activation of the nuclear receptor peroxisome proliferator activated 
receptor-gamma (PPARγ) has potential to disrupt the function of adipose, bone and the 
immune system. Furthermore, PPARγ is activated by structurally diverse environmental 
chemicals found in both the indoor and outdoor environments. A cumulative measure of 
PPARγ activity could be used to investigate relationships between activity and PPARγ 
related health outcomes. In this study, we investigate PPARγ agonist exposure in a 
population of women with extensive environmental chemical biomarker data using our 
recently developed Serum PPARγ Activity Assay (SPAA).  
 
Methods: Serum samples and biomonitoring data on 135 environmental and consumer 
product chemicals were available from women participating in a Danish based 
biomonitoring study, Snart Foraeldre (SF)/Milieu. We quantified the activity of PPARγ 
agonists in SF/Milieu serum samples (N=73) using the SPAA, a human PPARγ1-based 
reporter assay, and compared the PPRE transcriptional activities to a U.S. based 
commercial human serum sample and human serum with known concentrations of fatty 
acids (endogenous PPARγ ligands). We identified chemicals measured in the SF/Milieu 
cohort that potentially act as PPARγ agonists using data from the primary literature and 
EPA’s ToxCast and tested their ability to induce PPRE transcriptional activity in the 
SPAA. Using individual dose-response curves and a mixtures method, we generated 
predictions of PPARγ activation by the mixtures of select chemicals that were measured in 




Results: Serum samples from the SF/Milieu study induced a range of activities in the 
SPAA. SF/Milieu cohort serum PPRE transcriptional activities were non-zero, but lower 
than a U.S commercial human serum sample. SPAA results of the serum samples were not 
correlated with concentrations of the probable PPARγ agonists. We confirmed the ability 
of the probable PPARγ agonists to induce PPARγ-dependent transcriptional activity and 
showed that they possess a range of potencies and efficacies. Using the dose response data 
and concentrations of chemicals found in the SF/Milieu cohort serum, we predicted a low 
cumulative PPRE transcriptional activity for a mixture of a subset of environmental 
chemicals. 
 
Conclusions: Overall, the PPRE transcriptional activity of the Danish serum samples was 






Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor 
and ligand activated transcription factor that is widely expressed and responsive to 
structurally diverse ligands. PPARγ1, one of two isoforms of PPARγ in mammals, is 
broadly expressed in tissues throughout the body such as the liver, muscle, heart, spleen, 
adipose, brain, and kidney [22, 23, 233]. Endogenous ligands for PPARγ include fatty acids 
and prostaglandins [26, 189]. Exogenous ligands for PPARγ include natural dietary 
constituents, environmental chemicals, and synthetic drugs. Thiazolidinediones, a class of 
synthetic drugs including rosiglitazone and pioglitazone, are used in the treatment of type 
2 diabetes because they upregulate PPARγ’s insulin sensitizing functions [32, 183]. 
Research has focused on PPARγ’s action in adipose tissue and promotion of insulin 
sensitivity. Ligand activation of PPARγ induces the expression of genes that are necessary 
for adipose tissue development and function [16, 17, 234]. However, the biological effects 
of PPARγ extend across the body. PPARγ also regulates bone homeostasis and immune 
response [19, 20, 42, 235]. Activation of PPARγ by rosiglitazone, a potent therapeutic 
ligand, suppresses osteoblast formation and induces adipogenesis resulting in decreased 
bone formation [44]. As a result, patients using rosiglitazone experienced increased risk of 
bone fracture [33]. Additionally, activation of PPARγ exerts anti-inflammatory effects. For 
instance, in the central nervous system, activation of PPARγ has been proposed as 
protective of neurodegeneration due to the anti-inflammatory effects in microglia and 
astrocytes [45, 236].  




PPARγ ligands, including phthalates, organotins, brominated flame retardants, 
organophosphate esters (OPEs), and polycyclic aromatic musks, which induce 
adipogenesis [52, 55, 61, 67, 74, 191, 192]. In addition to inducing adipocyte 
differentiation in vitro, at least phthalates, organotins, and OPEs also increase adiposity in 
vivo [64, 77, 193, 194]. Furthermore, evidence suggests that, like rosiglitazone, phthalates, 
OPEs, and phthalates also decrease osteogenesis and compromise bone quality [60, 195, 
195]. Human epidemiological studies have begun to make the connection between 
exposure to environmental ligands that activate PPARγ such as perfluoroalkyl substances, 
phthalates, parabens, phenols, and organophosphate esters and health outcomes like 
obesity, diabetes, and osteoporosis [94, 99, 100, 107, 237-242].  
Cumulative assessments of ligand induced PPARγ activity are warranted in light of 
the facts that humans are exposed to multiple environmental and consumer product 
chemicals that activate PPARγ and that PPARγ regulates important biological functions. 
Efforts towards understanding the cumulative impacts of chemical mixtures and the 
combined effect of chemical and non-chemical stressors on health outcomes are increasing 
[243]. Here, we investigate the exposure to environmental and consumer product chemicals 
in the Snart Foraeldre/Milieu study, a prospective cohort study of pregnancy planners in 
Denmark [244] [245]. This study was designed to investigate exposures to environmental 
chemicals in the preconception period. In the biomonitoring portion of the study, serum 
and urine samples were analyzed for 135 environmental and consumer product chemicals. 
The most commonly detected chemical classes were phthalates, metals, phytoestrogens, 




aromatic hydrocarbons, and with few exceptions, the geometric means were lower in 
women from the Snart Foraeldre/Milieu cohort compared to women from the National 
Health and Nutrition Examination Survey (NHANES) [246].  
We used a novel biomarker of exposure, the Serum PPARγ Activity Assay (SPAA), 
to examine the associations between chemical exposures and increased serum PPARγ 
agonist activity. SPAA was previously developed in our laboratory as a simple, 
inexpensive bioassay to assess exposure to PPARγ ligands [247]. In this study, we used the 
SPAA to assess the cumulative PPARγ activity of the serum samples. We identified which 
of the chemicals previously measured in the serum samples were probable PPARγ agonists 
and generated dose response analyses for these compounds using SPAA. We then tested 
the hypothesis that the probable PPARγ agonists identified in the Snart Foraeldre/Milieu 
serum contribute to total PPARγ activity of serum as measured by SPAA. Using the 
generated dose-response curves for individual agonists, we predicted the activity of 
mixtures of chemicals measured in the serum, based on our knowledge of how mixtures of 
agonists behave in activating PPARγ [201], and compared this prediction to the serum-
induced activity.  
 
Experimental Methods 
Materials. Rosiglitazone (71740) was obtained from Cayman Chemical (Ann 
Arbor, MI). DMSO (cat# AB03091) was from American Bioanalytical (Natick, MA). 
Triclosan (cat #220326), daidzein (cat# 24001), perfluorodecanoate (PFDEA) (cat# 




perfluorooctane sulfonate (PFOS) (cat# 235283), and genistein (cat# 3515) were from 
Santa Cruz Biotechnology, Inc. (Dallas, TX). Butylparaben (cat# B1217000), ethylparaben 
(cat# E2425000), methylparaben (cat# M8911), propylparaben (cat# P5337), monobenzyl 
phthalate (MBzP) (cat# 89505), mono-2-ethylhexyl phthalate (MEHP) (cat# 796832), 
bisphenol A (BPA) (cat# 23965), perfluorooctanoate (PFOA) (cat# 171468), enterodiol 
(cat# 45198), and 2,2′,4,4′-tetrabromodiphenyl ether (PBDE-47) (cat# 91834) were all 
from Sigma-Aldrich (St, Louis, MO). All other reagents were from Thermo Fisher 
Scientific (Suwanee, GA), unless specified. 
Human Sera Standards. A human serum sample collected in the United States was 
purchased from Gemini Bio-products (West Sacramento, CA). SRM #2378 purchased 
from the National Institute of Standards and Technology (Gaithersburg, MD) contains 
three vials of serum with known concentrations of fatty acids. Serum 1 was collected from 
healthy donors who took 1000 mg/day of fish oil supplements; Serum 2 was collected from 
donors who took 1000 mg/day of flaxseed oil supplements; and Serum 3 was collected 
from donors who did not take either fish or flaxseed oil supplements for one month prior 
to collection. Analysis of the concentrations of fatty acids in each sample was performed 
by NIST and the Centers for Disease Control and Prevention (CDC).  
SF/Milieu Human Serum and Urine Samples. Seventy-three human serum samples 
analyzed by SPAA were provided from a previously established prospective cohort study 
of Danish women trying to conceive. The Snart Foraeldre/Milieu study (‘Soon 
Parents/Environment’) is a biomonitoring sub-study of Snart Foraeldre (SF) [244, 245]. 




methods have been previously published [244, 245, 248, 249]. The SF/Milieu study was 
approved by the Danish Data Protection Board (2006-41-6864), the North Denmark 
Region Committee on Health Research Ethics (N-20100087) and the Institutional Review 
Board at Boston University and informed consent was obtained from all participants. For 
the current analysis, procedures were determined not to constitute engagement in human 
subjects research by the Institutional Review Board at Boston University. 
Briefly, Danish women from the general population were recruited for the SF study 
through advertisements on social media, blogs, a Danish health-related website, and word 
of mouth. Eligible women were 18–40 years, in a stable relationship, and were not using 
contraception or fertility drugs. In the biomonitoring sub-study SF/Milieu, women lived in 
the city limits of Aalborg and met all of the above eligibility requirements. Between 
November 2011 and December 2014, 223 women enrolled and completed the baseline 
questionnaire, and a total 129 women agreed to participate in the SF/Milieu study. Urine 
and blood were collected at the clinical research laboratory at Aalborg University Hospital. 
Biospecimen collection occurred during the preconception period and during the 1st and 
2nd trimesters if pregnancy occurred.  
Blood and urine samples were collected in accordance with protocols used for 
biomonitoring in NHANES [148]. Whole blood was collected by a trained phlebotomist 
and allowed to clot for 2 hours before being centrifuged, transferred to cryovials and frozen 
at -80 ºC for shipment to the CDC for chemical analysis. Urine samples were collected 
from study participants and frozen at -20 ºC until shipped to the CDC for chemical analysis. 




(CDC) laboratory was determined not to constitute engagement in human subjects’ 
research. Detailed description of the SF/Milieu study biospecimen study analysis is 
reported elsewhere [246]. Biomarker data for chemicals in serum and urine were available 
for the 73 women whose serum was analyzed by SPAA. Due to improper mixing of some 
urine samples in the field, the total number of participants with urinary biomarker data is 
56 [246]. 
PPARγ agonist identification. Biological samples were previously assessed for a 
total of 135 chemicals. Analytes were chosen based on whether they were currently being 
measured as a part of NHANES; thus, the choice of analytes was not made with respect to 
potential PPARγ activity [246]. We used high-throughput assay information from EPA’s 
ToxCast Dashboard and evidence from the primary literature to identify chemicals as 
probable PPARγ agonists and prioritize them for testing in our assay. Metals (N=28) and 
cotinine were also measured in the biological samples. While some heavy and trace metals 
are suspected endocrine- and metabolic- disruptors, many metals act through pathways that 
are distinct from PPARγ or their mechanisms of action are unlikely to affect measured 
PPRE transcriptional activity in our assay [250, 251]. Therefore, our analyses focused on 
the remaining 106 environmental and consumer product chemicals.  
The EPA’s iCSS ToxCast Dashboard contains chemical and assay information 
from the Toxicity Forecaster (ToxCast) project and the Toxicity Testing in the 21st century 
(Tox21) collaboration. Assay information was downloaded in June 2017 
(https://actor.epa.gov/dashboard/) [253]. Chemicals were identified as agonists for PPARγ 




human PPARγ assay. The Attagene assay is a reporter assay using a GAL4 partial PPARγ 
receptor, and the Novascreen assay is a human PPARγ receptor binding assay. Positive 
results from both assays suggest that a chemical is both an agonist for and binds to PPARγ.  
We also screened the 106 measured chemicals for PPARγ activity using a search 
of the primary literature. All in vitro or animal studies published in English and available 
on Pubmed and Google Scholar were considered. Keywords in searches included the 
chemical name and/or acronym with “peroxisome proliferator activated receptor gamma”, 
“PPARγ”, “obesogen”, “adipogen”, and “adipogenic”. Inclusion criteria included any in 
vitro or animal studies with information on chemicals activating PPARγ in a cell-based 
assay, inducing adipocyte differentiation or inducing expression of a specific PPARγ target 
gene. Adipocyte differentiation occurs through activation of PPARγ due to treatment of 
cells with an adipogenic cocktail that increases its expression [129, 253]. Adipocyte 
specific fatty acid binding protein (abbreviated as ap2 or FABP4) is a target gene of PPARγ 
and commonly used as a marker of PPARγ activity [234].  Reporter assay studies were 
required to have a relevant positive control. Chemical concentrations that statistically 
significantly increased lipid accumulation for adipocyte differentiation studies or gene 
expression compared to vehicle or control are reported. 
Serum PPARγ Activity Assay. SF/Milieu serum samples were stored at -80°C prior 
to analyses. Detailed methods for performing the assay are provided elsewhere [247]. 
Briefly, Cos-7 cells were plated in 96-well plates in antibiotic free media and transiently 
transfected with the expression vector human PPARG1 (provided by V.K. Chatterjee, U. 




eGFP (mammalian expression vector for expression of green fluorescent protein) reporter 
constructs. Naïve wells were transfected with the reporter constructs alone and an empty 
pcDNA 3.1 plasmid (in proportion to the expression vectors). Transfected cultures were 
incubated overnight, and the media was replaced. Standard curve wells received 10 µl 
charcoal-dextran stripped FBS (referent) and were treated with Vh (DMSO, 0.5%) and 
rosiglitazone (10-10-2 x 10-6 M). Activity induced by FBS stripped with charcoal dextran 
(referent), which removes lipophilic contaminants and fatty acids, served as the 
background activity reference value [254]. As an internal check, rosiglitazone standard 
curves were compared to our historical standard curves [247]. Experimental wells received 
human serum (SF/Milieu, Gemini, and NIST human serum samples) and charcoal-dextran 
stripped FBS (referent) in triplicate (10 µl). Wells used for data normalization received 2 
x 10-7 M rosiglitazone and naïve wells were left untreated. After a 24hr incubation, cells 
were lysed using Steady-Luc Firefly HTS Reagent (Biotium, Freemont, CA). 
Luminescence (lum) and fluorescence (eGFP or flo) were measured using a Synergy2 
multi-function plate reader (Biotek, Inc. Winooski, VT). Data were normalized using a 
method to minimize intra- and inter-experimental variation [215]. eGFP values were 
analyzed to ensure that no treatment caused a significant decrease in fluorescence, an 
indicator of toxicity. Rosiglitazone-treated cultures (2x10-7 M) served as the positive 
control for PPARγ-transfected cultures. PPRE transcriptional activity is reported as the % 
Maximum Activity relative to the positive control. 
All chemicals identified as probable PPARγ agonists were then tested in the SPAA 




generated, and control wells were treated as described above. The standard curve wells 
containing 100 µl of medium were treated with vehicle (DMSO, 0.5%) and rosiglitazone 
(10-10- 2 x 10-6 M). Experimental wells were treated with individual chemicals: 
monobenzyl phthalate (MBzP) (10-8- 4x10-3 M), mono-(2-ethylhexyl) phthalate (MEHP) 
(10-8-10-3 M), propylparaben (10-8-10-3 M), butylparaben (10-7-2x10-4 M), ethylparaben 
(10-7-2x10-3 M), bisphenol A (10-8-2.5 x 10-4 M), triclosan (10-8-2 x 10-5 M), equol (10-8-4 
x 10-4 M), daidzein (10-8-4 x 10-4 M), enterodiol (10-9-4 x 10-4 M), genistein (10-8- 4 x 10-4 
M), 1-hydroxypyrene (10-8-10-4 M), 3-phenoxybenzoic acid (10-8- 4 x 10-4 M), 2,2',4,4'-
tetrabromodiphenyl ether (PBDE-47) (10-10-10-3 M), perfluorodecanoic acid (PFDeA) (10-
8- 2 x 10-4 M), perfluorohexanesulfonic acid (PFHxS) (10-8-10-3 M), perfluorooctanoic acid 
(PFOA) (10-8- 4 x 10-4 M), and perfluorooctanesulfonic acid (PFOS) (10-8-10-3 M). For a 
subset of chemicals used in mixtures modeling, serum adjusted chemical dose-response 
curves were generated. For serum adjusted chemical dose-response curves, cells received 
10 µL charcoal-dextran stripped FBS (referent) were treated with vehicle (DMSO, 0.5%), 
PFOA (10-11- 4 x 10-4 M), PBDE-47 (10-14-10-3 M), PFDeA (10-11- 2 x 10-4 M), PFHxS 
(10-11-10-3 M), and PFOS (10-9-10-3 M). The lower chemical doses correspond to the 
concentrations of the chemicals measured in the SF/Milieu cohort serum samples. PPRE 
transcriptional activity (% Maximum Activity) was calculated as described above. 
Statistical Analyses. Descriptive statistics of measured chemicals were conducted 
in SAS version 9.3. In the SF/Milieu cohort, concentrations below the limit of detect (LOD) 
were replaced by the LOD divided by the square root of two. Spearman correlations with 




Statistical analyses for in vitro experiments were performed with Prism 8 
(GraphPad Software, San Diego, CA). For reporter assays, serum samples were run in 
triplicate. Standard curves were fit with a Hill function with a Hill coefficient of 1 as this 
model is pharmacologically appropriate for PPARγ  and has been shown previously to fit 
empirical PPARγ activation data [201]. Testings for normality was conducted using 
Shapiro-Wilk. ANOVA combined with Dunnett’s or Tukey-Kramer multiple comparisons 
test were used to determine statistical significance. All analyses were performed using 
α=0.05.  
PPRE transcriptional activities of chemicals measured in serum were estimated 
using generalized concentration addition approximated by effect summation. We have 
previously shown that the activity of mixtures of full and partial PPARγ agonists are well 
fit by a generalized concentration model (GCA) for a receptor with a single binding site 
[201]. For mixtures of two compounds A and B, the model is 














where y is overall activity, αi is efficacy of compound i and Ki is the EC50. At low doses 
(A<<Ka and B<<Kb), this is closely approximated by 






































= 𝑓𝑎([𝐴]) +  𝑓𝑏([𝐵]) 
where fa([A]) and fb([B]) are the individual dose response curves. The GCA model is 
therefore approximated by effect summation at low doses where the dose-response curves 
are linear. The linearity of the model has been empirically verified [201]. In these models, 
the background activity is treated as zero. Hence, for empirical data, the background 
activity is subtracted before analysis.  
 For each participant, PPRE transcriptional activities were estimated based on the 
concentration of the chemical measured in a participant’s serum sample. Activities were 
estimated from each chemical’s serum adjusted dose-response curve using the “interpolate 
from a standard curve” function in Prism 8, and the background activity (i.e. activity of the 
referent) was subtracted. For the final mixtures model, we summed the estimated activities 
of each chemical along with the serum background activity from the referent to produce a 
final estimation of total PPARγ activity.  
 
Results 
Quantification of PPARγ transcriptional activity in human serum samples using 
SPAA. Our rosiglitazone standard curve strongly correlates with our historical standard 
curves, confirming the reproducibility of the assay and proper functioning of our positive 
control (Figure S4.1). The serum samples from the SF cohort induced a range of detectable 
activities (Figure 4.1A), which were not normally distributed (Shapiro-Wilk test p=0.01) 




background activity reference value, referred to as the referent; this value was generated 
using fetal bovine serum stripped (FBS) with charcoal dextran, which removes lipophilic 
contaminants and fatty acids [254] (Figure 4.1B). Approximately 30% of the SF/Milieu 
serum sample activities fell at or below this value. Both the median and maximum activities 
from the SF/Milieu serum samples were above the background level. The mean activity 
induced by the SF/Milieu serum samples was statistically higher than the referent activity 
(p<0.05). Second, we previously showed that commercial human serum samples from the 
United States induced significant PPARγ transcriptional activity [247]; therefore, we 
compared the activities in the SF/Milieu serum samples to the activity induced by the most 
efficacious U.S. serum sample (Figure 4.1B). The mean, median, and maximum activities 
from the SF/Milieu serum samples were below that induced by the U.S. serum sample. The 
activity induced by Gemini was statistically different than the mean activity induced by the 
SF/Milieu serum samples (p<0.05). 
Probable PPARγ agonists in the Snart Foraeldre/Milieu cohort. Urine and serum 
samples were collected from 73 non-pregnant women and assessed for 135 environmental 
and consumer product chemicals from different classes [246]. Biomarkers measured in 
urine included diakylphosphate metabolites, herbicides, metals, N,N-diethyl-meta-
toluamide (DEET) and three metabolites, parabens, phenols, phthalate metabolites, 
phytoestrogens, polycyclic aromatic hydrocarbon (PAHs) metabolites, organophosphate 
and pyrethroid insecticides metabolites, and perchlorate. In serum, biomarkers measured 
included brominated flame retardants, organchlorine pesticides, polychlorinated biphenyls 




We identified 19 chemicals, all measured in at least 50% of SF/Milieu samples, as 
probable PPARγ agonists (Table 4.1). Descriptive statistics of these chemicals are available 
in the supplemental material (Table S4.1). Using the Attagene and Novascreen assay data 
from EPA’s ToxCast Dashboard, we identified 7 chemicals as probable PPARγ agonists: 
MEHP, 3-phenoxybenozoic acid, 1-hydroxypyrene, PFHXS, PFOA, PFOS, and PFDEA 
as probable PPARγ agonists. Twelve additional probable PPARγ agonists were identified 
by a review of the literature: phthalates (MEHP, MBzP), PFASs (PFOS, PFOA, PFDEA, 
PFHXS), phenols (bisphenol A, triclosan), parabens (methyl-, butyl-, propyl-, 
ethylparaben), phytoestrogens (daidzein, equol, enterodiol, genistein), PBDE-47, and 1-
hydroxypyrene. Literature search and EPA ToxCast Dashboard results for all chemicals 
are available in the supplemental material (Table S4.2).   
We tested the 19 probable PPARγ agonists in the SPAA to characterize their 
potency and efficacy. All induced some PPRE transcriptional activity above Vh (Figure 
4.2); Table 4.2 provides additional information on dose response characteristics. For 
triclosan, bisphenol A (Figure 4.2D), 1-hydroxypyrene (Figure 4.2G), and PFDEA (Figure 
4.2H), full dose-response curves could not be generated because of overt toxicity at higher 
doses; therefore, EC50s were not calculated. Curve maximas and EC50s are presented in 
Table 4.2. Rosiglitazone, the PPARγ positive control, was potent and efficacious at 
activating PPARγ. With the exception of genistein, which had an efficacy similar to 
rosiglitazone, the remainder of chemicals had lower efficacies. Rosiglitazone was 




Fatty acids and fatty acid-derived compounds are known endogenous PPARγ 
ligands [26]. In Cos-7 cells transfected with human PPARG1, the fatty acids oleic acid, 
linoleic acid, palmitic acid, eicosapentaenoic acid and steric acid, at concentrations up to 
10-4 M, did not induce PPARγ1 transcriptional activity (data not shown). However, 
arachidonic acid and the arachidonic acid metabolite 15-deoxy-Δ12,14Protaglandin J2 
significantly induced PPRE transcriptional activity (Figure S4.2). PPRE transcriptional 
activities of three NIST serum samples with known concentrations of fatty acids were 
lower than the median and maximum activities of SF/Milieu cohort samples (Figure S4.3 
vs. Figure 4.1B). Two did not induce activity above background. The NIST sample with 
the highest arachidonic acid concentration induced the highest activity, which was slightly 
above the referent (Figure S4.3: Fatty acids: NIST 2). These data suggest that endogenous 
fatty acids are likely to make only a minimal contribution to the measured PPARγ agonist 
activity. 
Association of exposure biomarkers with PPRE transcriptional activity. Individual 
chemicals measured in the SF/Milieu cohort were not correlated with measured PPRE 
transcriptional activity induced by the SF/Milieu cohort serum samples (Table 4.3). 
However, correlations with individual compounds do not take into account cumulative 
activity. We therefore applied generalized concentration addition (GCA), as approximated 
by effect summation in the low dose region. For compounds measured in urine, there was 
insufficient pharmacokinetic data to estimate serum concentrations. Thus, we restricted our 
cumulative estimate to the subset of probable PPARγ agonists detected in serum: PBDE-




We generated individual chemical dose-response curves to estimate the PPRE 
transcriptional activity for our mixtures model. Dose responses were generated in the 
presence of excess serum to mimic the conditions in the serum analysis. The addition of 
serum increased the background activity, but the shape of the curve was unchanged (e.g. 
PFHxS: Figure 4.3A). Geometric means, minimum, and maximum concentrations of 
PBDE-47 and the PFAS in SF/Milieu cohort (Figure 4.3B) all fall in the low dose range of 
their respective dose response curves (i.e. well below the EC50s) as shown by comparison 
to Figure 4.2. Next, we estimated PPRE transcriptional activities for each of the five 
chemicals at the concentrations measured in participants. Along with the geometric mean, 
minimum, and maximum concentrations of the chemicals, we show their estimated PPRE 
transcriptional activities (Figure 4.3B). In Figure 4.3C, we show the average estimated 
PPRE transcriptional activity, by chemical, for the entire SF/Milieu cohort and the average 
final predicted activity of the mixture approximated by effect summation for the cohort. At 
the concentrations measured in the SF/Milieu serum samples, PFOA, PFOS, and PBDE-
47 all induced very low PPRE transcriptional activity. PFHxS, PBDE-47, and PFDeA did 
not induce activity above background, and majority of the total estimated activity is from 
the serum background activity. These data suggest that at the concentrations present in this 
cohort, this small set of environmental PPARγ agonists minimally contribute to the 






The Serum PPARγ Activity Assay (SPAA) is a simple, cell-based assay designed 
to detect exposure to PPARγ agonists by measuring total PPRE transcriptional activity in 
small volumes of human serum. Here, we quantified PPRE transcriptional activity in serum 
samples collected from a cohort of women enrolled in a Danish-based prospective study. 
Serum samples from the SF/Milieu cohort induced a range of activities in the SPAA above 
the referent sample. Overall, the low PPRE transcriptional activities induced by SF/Milieu 
serum samples suggest low levels of exposure to environmental PPARγ agonists in this 
cohort. 
A potential source of the SPAA activity is endogenous ligands. However, fatty 
acids activate PPARγ with low potency and efficacy. In a study comparing the fatty acids, 
palmitic, oleic, erucic, linoleic, arachidonic, eicosapentaenoic, and docosahexaenoic acid, 
arachidonic acid was the most efficacious at inducing PPARγ activity [255]. In our assay, 
fatty acids, both individually and in mixtures in human serum, minimally induced PPRE 
transcriptional activity. Fatty acid concentrations reported in NIST were only marginally 
higher than concentrations of serum fatty acids in U.S. adults reported by Sera et al., yet 
the NIST samples did not induce activity that was statistically greater than the referent 
[256]. While both arachidonic acid and its metabolite 15-deoxy-Δ12,14-Prostaglandin J2 
(15d-PGJ2) induced activity in the assay, the NIST sample with the highest concentration 
of arachidonic acid failed to induce activity greater than the background. Furthermore, 
prostanoids, a family of lipid mediators that includes prostanglandins, are produced within 




that high concentrations of 15d-PGJ2 will be found in serum samples [257]. We therefore 
explored the potential for the measured chemicals to contribute to SPAA.  
We used 135 urine and serum biomarkers of the women to identify environmental 
and consumer product chemicals that could potentially contribute to the PPRE 
transcriptional activity induced by the serum samples. A previous study found a lack of 
agreement between ToxCast PPARγ assays and their own experimental results testing 
chemicals. Only 5 of the 21 chemicals identified in ToxCast activated PPARγ in both the 
Attagene and Novascreen assays, and the rest were inactive [258]. Thus, it was useful to 
use multiple approaches to identify PPARγ agonists. We identified 19 probable PPARγ 
agonists from our search of EPA’s ToxCast database and the primary literature. All 19 
probable PPARγ agonists significantly induced PPRE transcriptional activity, although 
with a range of efficacies and potencies.  
We used the dose response analyses of individual chemicals in the SPAA to 
estimate their potential contribution to the serum PPRE transcriptional activity. Due to lack 
of pharmacokinetic information for estimating serum concentrations of active compounds 
from urine concentrations, we limited our analysis to the chemicals measured in serum: 
PFOA, PFDeA, PFOS, PFHxS, and PBDE-47. Previously, we have demonstrated that 
GCA accurately predicts the PPARγ activity of partial and full agonists [201]. At low doses 
where the dose-response functions are linear, the PPARγ GCA model is approximated by 
effect summation. The concentrations of PFOA, PFDeA, PFOS, PFHxS, and PBDE-47, all 
fall within the low dose range of their respective dose-response curves. Accordingly, GCA 




these sera.  Overall, the predicted activity suggests that PFOA, PFDeA, PFOS, PFHxS, and 
PBDE-47 measured in the SF/Milieu serum samples contribute minimally to PPRE 
transcriptional activity.  
There were limitations in our ability to explain the contribution of 135 exogenous 
chemicals towards the measured serum PPRE transcriptional activity. First, our mixtures 
model only included the five chemicals measured in serum. Based on our in vitro analyses, 
phytoestrogens, phthalates, and parabens were moderately efficacious at inducing PPRE 
transcriptional activity in the SPAA. Although the lower potencies of these chemicals 
means higher concentrations in serum would be needed to induce significant activity. 
Second, our analysis only considered probable PPARγ agonists. Cumulative PPRE 
transcriptional activity is driven by mixtures of ligands. The overall low activity induced 
by serum samples could be a result of a combination of agonists and competitive 
antagonists. Additionally, exogenous chemicals that activate the retinoid X receptor 
(RXR), PPARγ’s heterodimeric partner, can reduce measured PPRE transcriptional 
activity [247]. Third, we were limited to only considering chemicals measured in a 
previously established biomonitoring study. It is possible that the exogenous chemicals 
responsible for measured activity were not measured in the SF/Milieu study, which 
provides a likely explanation for the lack of correlation between individual probable 
PPARγ agonists and measured PPRE transcriptional activity. An ideal biomonitoring study 
to test the applicability of the SPAA as an exposure biomarker would include data on 
environmental, pharmaceutical, and consumer product chemicals that act as PPARγ 




measured in serum [258] [259]. Additionally, along with serum sample collection, 
participant questionnaires could be used to understand potential exposure to environmental 
chemicals. For example, questions regarding diet, consumer product use, and potential 
occupational exposures.  
A comparison of the SF/Milieu biomonitoring data to U.S. NHANES data suggest 
that U.S. women are generally more highly exposed to environmental chemicals identified 
as probable PPARγ agonists in our analyses [246]. This is in line with the observation that 
the mean, median, and maximum activities in the SF/Milieu cohort were lower than the 
activity in a random serum sample from the US.  
 
Conclusion 
 In summary, these data demonstrate that the Serum PPARγ Activity (SPAA) assay 
can detect distinct PPRE transcriptional activities in serum samples from a cohort of young 
women from Denmark. The serum samples from the Danish cohort induced a range of 
activity in the SPAA, but with lower efficacy than a U.S. based commercial human serum 
sample. While individually tested environmental and consumer product chemicals 
measured in this cohort induce PPRE transcriptional activity in our assay, the 
biomonitoring data suggest that chemicals identified as probable PPARγ agonists are 
present in low concentrations. Both the measured PPRE transcriptional activity from the 
SPAA and the predicted PPRE transcriptional activity indicate that the small subset of 
probable PPARγ agonists in this cohort do not induce high levels of activity. 









Table 4.1. Of the 135 chemical measured biomarkers in the Snart Foraeldre cohort, 19 were identified as probable PPARγ 
agonists using data from the primary literature and EPA’s ToxCast/Tox21. 
 
 Literature Search EPA ToxCast/Tox21 
Chemical 
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Gal4 1e-5 M 20 100 








































Propylparaben Full length 
100 
µM 

































50 µM a -- [54] 
Active Active Full length 60 µM 4 15 
Full length 1e-4 M 2.7 4.1 20 µM 20 µM [55] 




Equol -- -- -- -- 20 µM -- [265] -- -- 
Enterodiol -- -- -- -- -- Not active [266] Not tested Not tested 
Genistein Full length 
9.3 
µM 















2.5 9.9 -- -- [85] Active Active 
Perfluoro-
octanoic acid  
Gal4 1e-4 M 50 100 -- -- [67] 
Active Active 






Gal4 1e-4 M 80 100 





















3.5 9.9 -- -- [85] Active Active 
aResults for adipocyte differentiation results not quantified, only expressed as images 
bNot active means chemical tested, dose(s) didn’t reach statistical significance or not active in ToxCast Assay 
cActive means active in ToxCast assay 






Table 4.2. Dose-response curve statistics for rosiglitazone (standard) plus 19 chemicals 
identified as probable PPARγ agonists in the Snart Foraeldre/Milieu cohort.  
 




Rosiglitazone 92.4 3.9 x 10-8 0.01, 0.02, 0.1, 0.2, 1, 2 
2,2’,4,4’-
tetrabromodiphenyl ether 
11.5 6.4 x 10-6 10, 100, 200, 400, 1000 
Genistein 85.7 8.4 x 10-6 20, 100, 200, 400 
Mono-2-ethylhexyl 
phthalate 
37.9 2.1 x 10-5 20, 100, 400, 1000 
Daidzein 55.3 2.5 x 10-5 100, 200, 400 
Equol 51.5 4.9 x 10-5 100, 200, 400 
3-phenoxybenzoic acid 52.1 6.2 x 10-5 100, 200, 400 
Butylparaben 46.9 8 x 10-5 40, 100, 200 
Propylparaben 47.6 8 x 10-5 100, 200, 400, 1000 
Enterodiol 8.7 8 x 10-5 200, 400 
Perfluorohexanesulfonic 
acid (PFHxS) 
28.1 1.1 x 10-4 20, 40, 100, 200, 1000 
Perfluorooctanesulfonic 
acid (PFOS) 
27.6 1.2 x 10-4 20, 40, 100, 200, 1000 
Ethylparaben 32.7 1.7 x 10-4 100, 200, 1000, 2000 
Monobenzyl phthalate 49.7 1.7 x 10-4 100, 400, 1000, 2000 
Perfluorooctanoic acid 
(PFOA) 
26.6 2.5 x 10-4 100, 400 
Bisphenol A 18.3 -- 100, 250 
Triclosan 8.4 -- 10, 20 
1-hydroxypyrene 9.3 -- 10, 20 
Methylparaben 22.4 2.5 x 10-4 N/A 
Perfluorodecanoic acid 
(PFDeA) 
25.3 -- 200 
a Curve maximum values estimated from standard curves and EC50s are fit estimates from 
dose-response curves fitted with 3-parameter Hill function with a Hill coefficient of one 
using Prism.  
b Doses statistically significant from Vh (p<0.05, ANOVA, Dunnett’s) 





Table 4.3. Individual chemicals measured in the Snart Foraeldre cohort that were identified 




Coefficient (p value) 
Perfluorooctanesulfonic acid (PFOS) 0.16 (0.19) 
Perfluorodecanoic acid (PFDeA) 0.16 (0.19) 
Perfluorohexanesulfonic acid (PFHxS) 0.11 (0.37) 
Perfluorooctanoic acid (PFOA) 0.08 (0.51) 
Genistein 0.09 (0.51) 
Daidzein 0.08 (0.57) 
Equol 0.07 (0.61) 
Enterodiol 0.05 (0.71) 
1-hydroxypyrene 0.08 (0.51) 
Monobenzyl phthalate (MBzP) 0.03 (0.84) 
Bisphenol A 0.04 (0.76) 
Propylparaben -0.13 (0.34) 
Methylparaben -0.07 (0.68) 







Figure 4.1. Serum samples from 73 female pregnancy planners enrolled in a Danish 
biomonitoring study, Snart Foraeldre/Milieu, induced a range of detectable activities in the 
Serum PPARγ Activity Assay. Cos-7 cells were transfected with reporter plasmids (PPRE-
luciferase reporter, CMV-GFP reporter) and a human PPARG1 expression vector. Cells 
were treated with 10 µl charcoal-stripped fetal bovine serum and 10 µl human serum 
samples in triplicate. Luminescence and fluorescence were measured after 24 hrs. Data 
were calculated relative to 200 nM rosiglitazone standard, as described in the Methods. (A) 
Distribution of the serum PPRE transcriptional activities measured in the Snart 
Foraeldre/Milieu cohort. Activities were non-normally distributed (p=0.01, Shapiro-Wilk 
test). X-axis represents maximum of the range for each group. (B) Comparison of the 
Serum PPARγ activities between the different types of serum samples. Mean, median, and 
maximum activities induced by Snart Foraeldre/Milieu cohort shown. Ref indicates wells 
that received dextran charcoal stripped fetal bovine serum. Gemini sample represents mean 













































































































































Figure 4.2. Environmental chemicals measured in the Snart Foraeldre cohort and identified as probable PPARγ ligands induce 
PPRE transcriptional activity at varying efficacies (scale of y-axes vary between graphs).  Cos-7 cells were transfected with 
reporter plasmids (PPRE-luciferase reporter, CMV-GFP reporter) and a human PPARG1 expression vector. Cells were treated 
with Vh (0.5% DMSO, reported as lowest concentration in each plot and is 10-fold lower than lowest chemical concentration.), 
rosiglitazone (10-10-2 x 10-6 M), monobenzyl phthalate (10-8- 4x10-3 M), mono-(2-ethylhexyl) phthalate (10-8-10-3 M), 
propylparaben (10-8-10-3 M), methylparaben (10-8-10-3 M), butylparaben (10-7-2x10-4 M), ethylparaben (10-7-2 x 10-3 M), 
bisphenol A (10-8-2.5 x 10-4 M), triclosan (10-8-2 x 10-5 M), equol (10-8-4 x 10-4 M), daidzein (10-8-4 x 10-4 M), enterodiol (10-
9-4 x 10-4 M), genistein (10-8- 4 x 10-4 M), 1-hydroxypyrene (10-8-10-4 M), 3-phenoxybenzoic acid (10-8- 4 x 10-4 M), 2,2’,4,4’-
tetrabromodiphenyl ether (10-10-10-3 M), perfluorodecanoic acid (PFDeA) (10-8- 2 x 10-4 M), perfluorohexanesulfonic acid 
(PFHxS) (10-8-10-3 M), perfluorooctanoic acid (PFOA) (10-8- 4 x 10-4 M), and perfluorooctanesulfonic acid (PFOS) (10-8-10-3 
M). Luminescence and fluorescence were measured after 24 hrs. Data were calculated relative to 200 nM rosiglitazone standard 
as described in the Methods. Data are reported as mean ± standard error (N = 3-4 independent transfections). Data were fit with 





















































































































































































































































































































































































































































































Figure 4.3. Predicted activity of PFASs and PBDE-47 by generalized concentration 
addition does not entirely explain activity induced by SF/Milieu serum samples. Cos-7 
cells were transfected with reporter plasmids (PPRE-luciferase reporter, CMV-GFP 
reporter) and a human PPARG1 expression vector. Standard curve wells received charcoal 
stripped FBS (referent) plus perfluorohexanesulfonic acid (PFHxS) (10-11-10-3 M) (shown), 
and perfluorooctanoic acid (PFOA) (10-11- 4 x 10-4 M), 2,2’,4,4’-tetrabromodiphenyl ether 
(10-14-10-3 M), perfluorodecanoic acid (PFDeA) (10-11- 2 x 10-4 M), and 
perfluorooctanesulfonic acid (PFOS) (10-9-10-3 M) (not shown). PPRE transcriptional 
activities were estimated for each participant based on the measured concentration of each 
of the 5 chemicals; activities were estimated from the serum adjusted chemical dose-
response curve. After subtracting the background referent activity, the estimated chemical 
activities are summed and the background referent activity is added back for the final 
mixtures model. (A) Serum adjusted standard curve for PFHxS is comparable to regular 
PFHxS standard curve. (B) Geometric mean, minimum, and maximum concentrations of 
probable PPARγ agonists measured in Snart Foraeldre/Milieu serum samples expressed in 
units of molarity. PPRE transcriptional activities for minimum and maximum 
concentrations estimated using generalized concentration addition as approximated by 
effect summation at low doses. (C) Mean PPRE transcriptional activity for each chemical 
and chemical mixture for entire Snart Foraeldre /Milieu cohort. Error bars demonstrating 
range of activities for cohort are shown, but too small to be seen. PFDeA, PBDE-47, and 
PFHxS did not induce any detectable activity above serum background. The white line 
separates total estimated chemical activity contribution from contribution of serum 
background. Dotted line represents maximum activity induced by Snart Foraeldre /Milieu 










Chemical Geomean Min.  Max.  Min. Max. 
Perfluorooctanoic acid 
(PFOA) 
3.75 x 10-9 4.83 x10-10 2.78 x 10-8 2.847 2.849 
Perfluorooctanesulfonic 
acid (PFOS) 
1.11 x 10-8 1.40 x10-9 3.24 x 10-8 1.449 1.455 
Perfluorodecanoic acid 
(PFDeA) 
5.23 x 10-10 1.95 x10-10 1.17 x 10-9 -- -- 
Perfluorohexanesulfonic 
acid (PFHxS) 









































































































Table S4.1. Descriptive statistics of 19 probable PPARγ agonists with at least 50% 












Serum 73 3.63 40.1 57 
Bisphenol A (ng/mL) Urineb 56 0.99 14.5 95 
Triclosan (ng/mL) Urine 56 1.82 1500 52 
Butylparaben (ng/mL) Urine 56 0.29 16.7 63 
Ethylparaben (ng/mL) Urine 56 2 233 52 
Propylparaben (ng/mL) Urine 56 1.67 794 86 
Methylparaben (ng/mL) Urine 56 18.15 750 96 
Monobenzyl phthalate (ng/mL) Urine 56 1.37 26.4 82 
Mono-2-ethylhexyl phthalate 
(ng/mL) 
Urine 56 0.75 4.4 50 
Daidzein (ng/mL) Urine 56 34.75 1070 98 
Equol (ng/mL) Urine 56 15.87 1070 98 
Enterodiol (ng/mL) Urine 56 82.11 10000 98 
Genistein (ng/mL) Urine 56 6.96 407 98 
1-hydroxypyrene (ng/L) Urine 72 59 1163.1 97 
3-phenoxybenzoic acid (µg/L) Urine 56 0.13 1.88 100 
Perfluorohexanesulfonic acid 
(ng/mL) 
Serum 73 0.31 1.2 100 
Perfluorooctanoic acid (ng/mL) Serum 73 1.55 11.5 100 
Perfluorooctanesulfonic acid 
(ng/mL) 
Serum 73 5.55 16.3 100 
Perfluorodecanoic acid (ng/mL) Serum 73 0.27 0.6 100 
a 2,4,5-trichlorophenoxyacetic acid identified, but dropped due to detection frequency of 
less than 40% 




Table S4.2. Results from PPARγ ligand identification search of 106 chemicals measures 

















1-hydroxynaphthalene Y active inactive N 
2-hydroxyphenanthrene N -- -- N 
1-hydroxypyrene Y active active N 
2-hydroxyfluorene Y not tested not tested N 
2-hydroxynaphthalene Y inactive inactive N 
1-hydroxyphenanthrene N -- -- N 
3-hydroxyfluorene Y active inactive N 
3-hydroxyphenanthrene N -- -- N 
4-hydroxyphenanthrene N -- -- N 
9-hydroxyfluorene N -- -- N 
3-diethyl-carbamoyl benzoic acid N -- -- N 
NnN-Diethyl-meta-toluamide Y inactive inactive N 
N,N-diethyl-3-
hydroxymethylbenzaminde 
N -- -- N 
2-(N-ethyl-perfluorooctane 
118ulfonamide) acetate 
N -- -- N 
2-(N-methyl-perfluorooctane 
118ulfonamide) acetate 
N -- -- N 
Perfluorodecanoate Y active active Y 
Perfluorohexane sulfonate Y active active Y 
Perfluorononanoate Y active inactive N 
Perfluorooctane sulfonamide Y active inactive N 
Perfluorooctanoate Y active active Y 
Perfluorooctane sulfonate Y active active Y 
Cyclohexane-1 2-dicarboxylic acid 
monohydroxy isononyl ester 
N -- -- N 
Mono-n-butyl phthalate Y inactive inactive N 






















Mono carboxyisononyl phthalate N -- -- N 
Mono carboxyisooctyl phthalate N -- -- N 
Mono-3-carboxypropyl phthalate N -- -- N 
Mono-2-ethyl-5-carboxypentyl 
phthalate 
N -- -- N 
Mono-2-ethyl-5-carboxypentyl 
phthalate 
N -- -- N 
Mono-2-ethyl-5-hydroxyhexyl 
phthalate 
N -- -- N 
Mono-2-ethylhexyl phthalate Y active active N 
Mono-2-ethyl-5-oxohexyl 
phthalate 
N -- -- N 
Monoethyl phthalate N -- -- N 
Mono-isobutyl phthalate N -- -- N 
Diethyldithiophosphate Y inactive not tested N 
Diethylphosphate N -- -- N 
Dimethyldithiophosphate N -- -- N 
Dimethylthiophosphate N -- -- N 
Diethylthiophosphate N -- -- N 
2,4-Dichlorophenoxyacetic acid Y active not tested N 
2,4,5-trichlorophenoxyacetic acid Y active active N 
4-fluoro-3-phenoxybenzoic acid N -- -- N 
3,5,6-Trichloro-2-pyridinol Y active not tested N 
3-phenoxybenzoic acid Y active active N 
2-isopropyl-4-methyl-6-
hydroxypyrimidine 
Y inactive inactive N 




N -- -- N 
Perchlorate N -- -- N 
Hexachlorobenzene Y not tested not tested N 
β-Hexachlorocyclohexane N -- -- N 
γ-Hexachlorocyclohexane 
(Lindane) 
N -- -- N 
Trans-Nonachlor N -- -- N 
2,2-Bis(4-chlorophenyl)-1,1-
dichloroethene 




















Y inactive not tested N 
2,2-Bis(4-chlorophenyl)-1,1-
trichloroethene 
Y inactive not tested N 
mirex Y inactive active N 
2,4,4'-triCB N -- -- N 
2,3',4,4'-tetraCB N -- -- N 
2,4,4',5-tetraCB N -- -- N 
2,3',4,4',5-pentaCB N -- -- N 
2,3,3'4,4'-pentaCB N -- -- N 
2,3,4,4',5-pentaCB N -- -- N 
2,3',4,4',5-pentaCB N -- -- N 
2,2',3,4,4',5-hexaCB and 
2,3,3',4,4',6-hexaCB 
N -- -- N 
2,2'3,4',5,5'-hexaCB N -- -- N 
2,2',4,4',5,5'-hexaCB Y -- -- N 
2,3,3',4,4',5-hexaCB N -- -- N 
2,3,3',2,4,4',5'-hexaCB N -- -- N 
2,3',4,4',5,5'-hexaCB N -- -- N 
2,2',3,3',4,4',5-heptaCB N -- -- N 
2,2',3,3',4,4',6-heptaCB N -- -- N 
2,2',3',4,4',5,5'-heptaCB N -- -- N 
2,2',3,4,4',5',6-heptaCB N -- -- N 
2,2',3,4',5,5',6-heptaCB Y inactive not tested N 
2,3,3',4,4',5,5'-heptaCB N -- -- N 
2,2',3,3',4,4',5,5'-heptaCB N -- -- N 
2,2',3,3',4,4',5',6-octaCB and 
2,2',3,4,4',5,5',6-octaCB 
N -- -- N 
2,2',3,3',4,5,6,6'-octaCB N -- -- N 
2,2',3,3',4,4',5,5',6-nonaCB N -- -- N 
DecaCB N -- -- N 
2,2',4-tribomodiphenyl ether N -- -- N 
2,4,4'-tribromodiphenyl ether N -- -- N 
2,2',4,4'-tetrabromodiphenyl ether Y inactive inactive Y 
2,3',4',4-tetrabromodiphenyl ether N -- -- N 
2,2',3,4,4'-pentabromodiphenyl 
ether 




















Y not tested not tested N 
2,2',4,4',6-pentabromodiphenyl 
ether 
N -- -- N 
2,2',4,4'5,5'-hexabromodiphenyl 
ether 
Y not tested not tested N 
2,2',4,4',5,6'-hexabromodiphenyl 
ether 
N -- -- N 
2,2',3,4,4',5',6-
heptabromodiphenyl ether 
N -- -- N 
2,2',4,4',5,5'-hexabromobiphenyl N -- -- N 
Daidzein Y active inactive Y 
O-Desmethyl-angolensin N -- -- N 
Equol N -- -- Y 
Enterodiol Y not tested not tested Y 
Enterolactone Y active not tested N 
Genistein Y active inactive Y 
24-dichlorophenol  Y inactive inactive N 
25-dichlorophenol  Y inactive not tested N 
Benzophenone-3  Y active not tested N 
Butylparaben Y active inactive Y 
Bisphenol a Y inactive inactive Y 
Ethylparaben Y active inactive Y 
Methylparaben Y inactive inactive Y 




N -- -- N 
Triclosan Y active active Y 
a Metals (N=28) and cotinine (N=1) not included 




Figure S4.1. Comparison of serum adjusted rosiglitazone standard curve from SPAA 
development to curve generated with Snart Foraeldre/Milieu serum samples. Cos-7 cells 
were transfected with reporter plasmids (PPRE-luciferase reporter, CMV-GFP reporter) 
and a human PPARG1 expression vector. Cells were treated with Vh (DMSO, 0.5%) or 
rosiglitazone (10-10 – 2 x 10-6) plus 10 µl charcoal-stripped fetal bovine serum. 
Experimental wells were treated with 10 µl human serum samples in triplicate. “Ref” refers 
to referent wells that received 10 µL of charcoal-stripped fetal bovine serum. 
Luminescence and fluorescence were measured after 24 hrs. Data were calculated relative 
to 200 nM rosiglitazone standard, as described in the Methods. Historical curve represents 















































2019 Curve EC50 = 7.8 x 10
-8 M




Figure S4.2. Fatty acids induce PPRE transcriptional activity in Cos-7 cells transfected 
with human PPARγ. Cos-7 cells were transfected with reporter plasmids (PPRE-luciferase 
reporter, CMV-GFP reporter) and a human PPARG1 expression vector. Experimental 
wells were treated with Vh (DMSO, 0.5%; reported as lowest concentration in each plot 
and is 10-fold lower than lowest chemical concentration), rosiglitazone (10-9-10-5 M), 
arachidonic acid (10-7-10-4 M) or 15-deoxy-Δ12,14-Prostaglandin J2 (10
-8-10-5 M). 
Luminescence and fluorescence were measured after 24 hrs. Data were calculated relative 
to 10 µM rosiglitazone standard, as described in the Methods.  Data are reported as mean 
± standard error (N = 3-4 independent transfections). Data were fit with a 3-parameter Hill 




















































































































































Figure S4.3. NIST human serum samples with known concentrations of fatty acids do not 
induced PPRE transcriptional activity beyond the serum background. Cos-7 cells were 
transfected with reporter plasmids (PPRE-luciferase reporter, CMV-GFP reporter) and a 
human PPARG1 expression vector. Cells were treated 10 µl charcoal-stripped fetal bovine 
serum or 10 µl human serum samples in triplicate. “Ref” refers to referent wells that 
received 10 µL of charcoal-stripped fetal bovine serum. Luminescence and fluorescence 
were measured after 24 hrs. Data were calculated relative to 200 nM rosiglitazone standard, 
as described in the Methods. Each sample represents mean of technical replicates across 
plates. Different letters indicate statistical significance. *Significantly different from Vh 





























































CHAPTER 5: Conclusions  
Overall, the goals of this research were to investigate the metabolic health effects 
associated with exposure to environmental PPARγ ligands and to develop an improved 
method to assess exposure to them using a multidisciplinary approach. First, in Chapter 2, 
we used our extensive knowledge of the toxicology of environmental PPARγ ligands to 
design an investigation of the association of urinary DPHP, a metabolite of TPHP, with 
biomarkers of type 2 diabetes and measures of adiposity using data from NHANES. We 
show that urinary DPHP is positively associated with body adiposity measures in adults in 
the U.S. general population. In Chapter 3, we developed a simple, cell-based bioassay to 
quantify total PPARγ ligand activity in serum samples. The SPAA provides a robust 
measure of the combined activity of mixtures of PPARγ ligands in whole serum. Last, in 
Chapter 4, we used the SPAA to quantify cumulative PPRE transcriptional activity in 
serum samples from a previously established cohort that was assessed for exposure to a 
total of 135 environmental chemicals. The SF/Milieu serum samples induced a range of 
activities, but with a lower efficacy than our most efficacious U.S. based human 
commercial serum sample. The predicted PPRE transcriptional activities modeled with 
GCA as approximated by effect summation indicated that PFASs and PBDE-47 exposure 
in this cohort do not contribute significantly to serum PPARγ agonist activity. However, 
the SPAA is an important step towards developing a biomarker of cumulative exposure to 
environmental PPARγ ligands.  
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Chapter 2: Environmental organophosphate ester exposure and diabetes and  
adiposity measures in the U.S. general population 
Evidence in in vitro and animal studies suggests TPHP disrupts metabolic health, 
potentially through PPARγ. Ligand activation of PPARγ induces the expression of genes 
necessary for adipose tissue development and function and promotion of insulin sensitivity, 
thus PPARγ is a therapeutic target for the treatment of type 2 diabetes. However, selective 
agonism provides a mechanism through which environmental ligands (e.g. TPHP) may act 
distinctly from therapeutic ligands. Environmental PPARγ ligands may activate a distinct 
PPARγ transcriptional program, compared to therapeutic ligands such as rosiglitazone, that 
disrupts adipose and metabolic homeostasis. For example, unlike rosiglitazone, TPHP 
maintains phosphorylation of PPARγ at the amino acid serine 273, which is linked to 
reduced insulin sensitivity and browning of fat [166, 232]. The generation of brown/brite 
fat can potentially counteract the development of metabolic disease. 
TPHP, a chemical found in both the indoor and outdoor environments, activates 
PPARγ and induces metabolic disruption in animal studies [74, 75, 77-79, 128]. Yet, the 
potential for TPHP to act as a metabolic disruptor in humans, specifically how it affects 
type 2 diabetes risk, had yet to be investigated. This study used biomonitoring and 
demographic data from NHANES to investigate the association between urinary DPHP, a 
metabolite of TPHP, and biomarkers of type 2 diabetes and measures of adiposity. Using 
multivariate linear regression models adjusted for relevant confounders, we found positive 
associations between urinary DPHP and all three measures of adiposity (WC, BMI, and 
SAD) in adults aged 20-50 years only.  
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Our findings with adiposity in young adults are consistent with animal studies 
showing increased weight gain and fat mass in rodents [77-79]. Animal studies also report 
increased early onset type 2 diabetes, insulin resistance and impaired glucose homeostasis 
in rodents following fetal exposure to TPHP [77-79]. We found no significant findings 
with markers of type 2 diabetes. The null findings with the biomarkers of type 2 diabetes 
risk could be attributed to our exclusion of participants with a diabetes diagnosis or 
participants currently taking diabetes medications to prevent a reduction in the estimated 
effect of exposure on the outcome. Alternatively, differences in the findings between 
animal and human studies could be attributed to the timing of exposure in the studies. 
Animal studies have focused on early life exposure to TPHP because developmental 
periods during early life are sensitive windows during which exposure to MDCs can 
increase susceptibility to disease later in life. The short half-life of TPHP means the urinary 
metabolite concentrations used in our analyses only reflect recent exposure (i.e. exposure 
during adulthood). Instead, early life exposure to TPHP might cause improper 
programming of metabolic organs and increase the risk of metabolic dysfunction long term. 
Future epidemiological studies should use multiple measures of urine collected throughout 
pregnancy to investigate body weight gain or insulin resistance in children later in life to 
understand the adverse metabolic health effects associated with early life TPHP exposure.   
One key limitation of this study is the potential exposure measurement error. This 
challenge is a result of several problems associated with the use of urinary DPHP as a 
biomarker of exposure to TPHP. First, urinary DPHP assessed in spot urine samples fails 
to accurately measure exposure over a period of time, which is important given that 
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changes in body adiposity occur over time. The half-life of TPHP is estimated to be hours 
to days while changes in body fat occur over the span of weeks to months [170]. Future 
studies should consider using repeated measures of DPHP, ideally in a study with a design 
that allows for determination of temporality between the exposure and outcome. Second, 
the use of urine excretion rate data to normalize the urinary chemical measure allowed us 
to avoid the biases associated with traditional creatinine correction and is a study strength. 
However, the urine excretion rates were calculated from self-reported data which 
introduces some additional error. While 24-hour urine collections are cumbersome, this 
would allow for a more accurate calculation of analyte excretion instead of relying on 
multiple spot samples [268].  
 Another challenge to the interpretation of the study findings is that DPHP was 
measured and not TPHP. The presence of DPHP in urine could be a result of exposure to 
other OPEs, instead of TPHP, that also are metabolized to DPHP (e.g. 2-ethylhexyl 
diphenyl phosphate or resorcinol bis(diphenyl phosphate) or exposure to DPHP itself since 
it is used in other products or found in the environment [127, 169, 269]. Another question 
that arises is: is it the parent, TPHP, or the metabolite, DPHP, that is biologically active? 
In vitro analyses suggest that DPHP is less efficacious at activating human PPARγ and less 
potent at inducing adipocyte differentiation and glucose uptake in 3T3-L1 cells than TPHP 
[128, 270]. A few studies suggest that TPHP is the more biologically active compound. 
Green et al reported increased obesity and onset of type 2 diabetes in rats exposed to TPHP; 
however, since the chemical was administered orally, first pass metabolism was in effect 
[77]. In another study, researchers exposed mice to TPHP or DPHP via subcutaneous 
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injection and reported weight gain only in mice exposed to TPHP [79]. Additional in vitro 
studies should investigate how other OPEs that metabolize into DPHP interact with PPARγ 
or other biological pathways related to metabolic health. Moreover, additional animal 
studies are needed to investigate the role, if any, of TPHP exposure on metabolic health 
throughout the life course.    
 
Chapter 3: Assessment of total, ligand-induced peroxisome proliferator activated 
 receptor γ ligand activity in serum. 
 In Chapter 2, we show that TPHP exposure is associated with adiposity measures 
in humans, yet an important unaddressed limitation of that study is that TPHP may not be 
the only chemical that could be contributing to adiposity. Here, we present the development 
of the SPAA, a simple and cost-effective method to measure total PPARγ ligand activity 
in small volumes of serum that is easily reproducible in any laboratory. The SPAA attempts 
to address a limitation of Chapter 2 by laying the foundation for a biomarker of cumulative 
exposure to mixtures of PPARγ ligands.  
Traditional exposure assessment focuses on characterizing exposure to a single 
chemical at a time. Chemicals are measured in human biological samples such as urine and 
serum and normalized, if necessary, by creatinine or specific gravity to correct for urine 
dilution or serum lipid adjusted for lipophilic chemicals in serum [171, 271]. There are 
numerous challenges to assessing human health risks to complex mixtures including how 
to characterize the potential combined or interactive effects associated with exposure to 
multiple chemicals. Regular regression models often cannot handle multiple, highly 
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correlated chemical exposures in one model, thus requiring advanced statistical models. 
Furthermore, toxicological studies are challenged with trying to test all possible 
combinations of a chemical mixture. PPARγ is a target for multiple exogenous chemicals 
found in the environment, pharmaceuticals, and consumer products, and inappropriate 
activation can increase the risk for obesity, type 2 diabetes, and osteoporosis. A biomarker 
of cumulative activity, along with biomonitoring data, could be used to connect cumulative 
environmental PPARγ ligand exposure to health outcomes in human epidemiological 
studies. 
First, we determined the necessary components to measure robust, PPARγ-driven 
PPRE transcriptional activity. We tested combinations of PPARγ and RXRα expression 
vectors and ligands. In line with our objective to develop a cumulative measure of PPARγ-
specific activity, we found that we can detect robust, rosiglitazone-induced PPRE 
transcriptional activity in Cos-7 cells transfected with only a PPARγ expression vector and 
that no activity was induced by the RXR ligand. Therefore, in the SPAA, we proceeded 
with transfecting Cos-7 cells with human PPARγ1, the PPRE reporter, and the control 
reporter (CMV-eGFP). Second, we tested the efficacy of SPAA to detect low levels of 
exogenous PPARγ ligands in serum from mice experimentally exposed to rosiglitazone 
and found we can detect as low as 10-7 M (or 100 nM) rosiglitazone in serum. Finally, 
SPAA detected significant differences in the PPRE transcriptional induced by U.S. based 




A limitation to SPAA is that PPARγ-RXRα is a permissive heterodimer, meaning 
that a ligand for either receptor can induce activity. Thus, the bioassay could potentially 
detect both PPARγ and RXR ligands. Co-exposure to PPARγ and RXRα ligands can 
synergistically increase transcriptional activity, at least in some cell types [217, 220]. The 
cell-specificity of this phenomenon is demonstrated by the observation that LG100268, a 
synthetic RXR ligand, increased rosiglitazone-induced Fabp4 expression (a direct PPARγ 
target gene) in THP1 cells but decreased rosiglitazone-induced Fabp4 expression in 
monocyte-derived macrophages and dendritic cells [228]. In SPAA, LG100268 decreased 
rosiglitazone-induced PPRE transcriptional activity. We hypothesize that this results from 
RXR homodimers binding to the PPRE site, liganded with LG100268, and inducing 
activity with less efficacy than the PPARγ-RXRα heterodimer. Undoubtedly, serum 
samples contain mixtures of ligands for both receptors, including antagonists and full and 
partial agonists. Both human commercial serum samples and mice sera induced activity in 
Cos-7 cells transfected with human RXRα alone, but with an overall lower efficacy than 
the activity induced in human PPARγ transfected cells. However, natural and endogenous 
RXRα ligands such as 9-cis-retinoic acid or docosahexaenoic acid that could be present in 
serum have lower potencies than the synthetic RXRα ligand LG100268 (EC50s: 15 nM, 50 
µM, and 2-5 nM respectively) [52, 272]. Thus, high concentrations of endogenous ligands 
would be needed to significantly decrease PPRE transcriptional activity.  
The SPAA provides a robust measure of combined activity of mixtures of PPARγ 
ligands. One possible use for the SPAA is in epidemiological analyses to investigate 
relationships between exposure to multiple environmental PPARγ ligands and adverse 
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health effects. However, measured activity from the SPAA alone is not enough to connect 
PPARγ ligand exposure to adverse health effects since environmental PPARγ ligands have 
distinct abilities to activate PPARγ’s functions. Thus, SPAA should be used in conjunction 
with environmental chemical biomonitoring data and/or effect directed analyses to improve 
understanding of the source(s) of PPARγ activation and how activity and exposure could 
be associated with PPARγ related health effects. 
 
Chapter 4: Investigation of serum PPARγ agonist activity in a cohort with well  
characterized chemical exposures 
 As mentioned above, ideally the SPAA would be used as an initial step in 
characterizing potential exposure to PPARγ ligands. Here, we tested the applicability of 
the SPAA as an exposure biomarker. We investigated PPARγ agonist exposure in serum 
samples from a cohort of women with extensive environmental chemical biomarker data. 
For this study, we took advantage of access to serum samples from the Snart Foraeldre 
(SF)/Milieu study, a prospective cohort study of pregnancy planners in Denmark.  
First, we used the SPAA to assess the cumulative PPARγ activation potential of the 
mixture of agonists in SF/Milieu human serum samples. Second, we used data from 
ToxCast and the literature to identify a subset of chemicals as PPARγ agonists. We 
generated dose-response analyses of these chemicals to test their ability to induce PPRE 
transcriptional activity in the SPAA. Third, we tested the hypothesis that the probable 
PPARγ agonists identified in the SF/Milieu serum would contribute to total PPARγ activity 
of serum as measured by SPAA. Serum samples from the SF/Milieu study induced a range 
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of activities in the SPAA, but with an overall lower efficacy than a U.S. based commercial 
human serum sample. Moreover, measured activity from the SPAA was not correlated with 
concentrations of the probable PPARγ agonists. We confirmed the ability of these 
chemicals to induce PPARγ-dependent transcriptional activity and showed that they 
possess a range of potencies and efficacies. Using the dose-response data and 
concentrations of chemicals found in the SF/Milieu cohort serum, we predicted a low 
cumulative PPRE transcriptional activity for a mixture of a subset of environmental 
chemicals. These results, in addition to a previous comparison of the SF/Milieu 
biomonitoring data to U.S. NHANES, suggest that exposure to environmental PPARγ 
agonists was low in the SF/Milieu cohort.  
A potential limitation of the study is that we cannot distinguish between activity 
induced by endogenous versus exogenous chemicals. Although, testing of fatty acids likely 
found at high concentrations in human serum and testing of human serum samples with 
known fatty acid compositions showed that fatty acids were unlikely to contribute to 
activity in SPAA. Furthermore, there were some limitations in our ability to completely 
explain the effect of environmental and consumer product chemicals on measured serum 
PPRE transcriptional activity. Because we used serum samples and biomonitoring data 
from a previously established cohort study, we were limited to only considering the 
chemicals measured as part of the SF/Milieu study. These chemicals were not chosen 
because they are PPARγ ligands; rather, these chemicals matched current chemicals 
measured in NHANES. Additionally, many chemicals were measured in urine, including 
14 of the 19 probable PPARγ agonists, and due to insufficient pharmacokinetic data, we 
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were unable to use the urinary measurements to estimate serum concentrations. As a result, 
our calculation of the predicted PPRE transcriptional only included 5 probable PPARγ 
agonists (i.e. chemicals measured in serum), which limited our ability to accurately 
determine the contribution of environmental chemicals towards measured activity.  
A comparison of the SF/Milieu biomonitoring data to U.S. NHANES data in a 
previous study suggests that U.S. women are generally more highly exposed to 
environmental chemicals [246]. Due to differences in chemical regulations, exposure to 
environmental chemicals in Europe and the U.S. can vary. This could explain the low PPRE 
transcriptional activity levels in the SF/Milieu cohort compared to the U.S. based 
commercial human serum. However, the U.S. NHANES dataset represents a more 
heterogenous population compared to SF/Milieu data since all the study participants 
resided in Aalborg, Denmark, which could explain the higher U.S. exposure levels. 
Similarly, the U.S. based human commercial serum sample used in our analyses is derived 
from a slightly larger sample size over a larger geographic area (200-250 volunteers across 
the U.S.).  
An ideal study design to test the applicability of the SPAA would include both men 
and women from the same country with serum tested for a variety of environmental and 
consumer product chemicals that act as agonists and antagonists for PPARγ and RXRα 
(PPARγ’s DNA binding partner). For example, sample collection could be limited to a few 
U.S. cities of similar population, demographic composition, and industry, and the activities 
could then be compared to the U.S. based commercial human serum sample. An alternative 
to associating SPAA results with biomonitoring data would be to use effect directed 
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analyses which combines biotesting, fractionation procedures, and chemical analysis to 
identify the most bioactive components of a complex chemical mixture.  
 
Public Health Implications 
 The rise in the global prevalence of obesity is an important public health concern 
because of the parallel increase in obesity-related comorbidities. Obesity significantly 
increases the risk for metabolic syndrome, a cluster of comorbidities that includes high 
blood pressure, high blood sugar, excess central adiposity, and dyslipidemia [3, 23], which 
in turn increases the risk for metabolic diseases (i.e. type 2 diabetes, atherosclerosis, non-
alcoholic fatty liver disease). While the etiologies of obesity and obesity-related conditions 
are multifactorial, there is growing recognition of the role of the environment as an 
additional risk factor. Accumulating evidence from toxicological and epidemiological 
studies supports the role of environmental metabolism disrupting chemicals (MDCs) in the 
development of obesity and type 2 diabetes. MDCs can act through a multitude of 
mechanisms, including nuclear receptor binding, to disrupt metabolic function.  
Our findings in Chapter 2 show that TPHP exposure is positively associated with 
measures of adiposity in young adults in the U.S. general population and are among the 
first to suggest that TPHP acts as a metabolic disruptor in humans. The use of OPEs in 
consumer and industrial products has increased dramatically since the phase out of 
polybrominated diphenyl ethers, stimulating many studies to document concentrations of 
TPHP in the environment and its metabolite in humans [104-106]. However, only a few 
studies have demonstrated the potential health risks associated with TPHP exposure. While 
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our findings should be interpreted cautiously, these results warrant the need for additional 
epidemiological studies to elucidate TPHP’s role in increasing the risk not only of obesity 
but also metabolic diseases.  
Because of its regulatory role in adipocyte differentiation and insulin sensitivity, 
PPARγ is a focal point for research identifying environmental MDCs. Environmental and 
consumer product chemicals that activate PPARγ include a growing list of structurally 
diverse compounds found in natural products, personal care products, plastics, and 
furniture [67, 74, 262]. In Chapter 3 and 4, we present the development and application of 
the SPAA as a biomarker of exposure to environmental PPARγ agonists. Importantly, these 
studies lay the foundation for future work using SPAA as a biomarker of cumulative 
PPARγ ligand exposure. This is important because only a small number of the tens of 
thousands of chemicals that have been registered for use in commercial products over the 
past decades have been assessed for their biological activity and potential toxicity. SPAA 
is an agnostic assay and addresses the critical need for exposure assessment measures that 
account for chemical mixtures. 
It is important not only to consider the effects of chemical mixtures on metabolic 
disruption, but also on other health effects related to PPARγ activity. PPARγ also regulates 
immune response and bone homeostasis [19, 20, 42, 235]. For example, it is well known 
that reduced bone quality, which increases fracture risk, is an adverse health effect 
associated with use of thiazolidinediones (i.e. therapeutic PPARγ ligands). Recent 
evidence from animal and in vitro studies also suggests that environmental ligands can 
reduce bone quality [60, 195, 196, 273-275]. A proper functioning skeletal system protects 
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vital organs, provides a structure to support movement, and serves as a storehouse of 
minerals. Thus, low bone quality (osteopenia) and osteoporosis pose a significant and 
costly burden on public health. Fractures and broken bones result in billions in healthcare 
and medical expenses, and once an osteoporotic fracture has occurred, life expectancy is 
reduced [276, 277].  
In summary, given PPARγ’s roles across multiple organ systems, environmental 
and consumer product chemicals that inappropriately activate the receptor can be additional 
risk factors for the development of metabolic diseases. Results from these studies broaden 
our understanding of the human health effects associated with environmental PPARγ 
ligand exposure. Furthermore, these findings suggest the potential application of the SPAA 
as a biomarker of exposure. Improved methods of characterizing environmental exposures 
in humans are critical in robust human epidemiological studies. These findings can be used 
to inform individuals in the public of changes they can make to reduce personal exposure 
and, ultimately, support regulatory and policy efforts that focus on strengthening chemical 
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